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MODEL-BASED APPROACH FOR DIFFUSE GLIOMA CLASSIFICATION, GRADING, 
AND PATIENT SURVIVAL PREDICTION  
Zeina A. Shboul 
Old Dominion University, 2020 
Director: Dr. Khan M. Iftekharuddin 
The work in this dissertation proposes model-based approaches for molecular mutations 
classification of gliomas, grading based on radiomics features and genomics, and prediction of 
diffuse gliomas clinical outcome in overall patient survival. Diffuse gliomas are types of Central 
Nervous System (CNS) brain tumors that account for 25.5% of primary brain and CNS tumors and 
originate from the supportive glial cells. In the 2016 World Health Organization’s (WHO) criteria 
for CNS brain tumor, a major reclassification of the diffuse gliomas is presented based on gliomas 
molecular mutations and the growth behavior. Currently, the status of molecular mutations is 
determined by obtaining viable regions of tumor tissue samples. However, an increasing need to 
non-invasively analyze the clinical outcome of tumors requires careful modeling and co-analysis 
of radiomics (i.e., imaging features) and genomics (molecular and proteomics features). The 
variances in diffuse Lower-grade gliomas (LGG), which are demonstrated by their heterogeneity, 
can be exemplified by radiographic imaging features (i.e., radiomics). Therefore, radiomics may 
be suggested as a crucial non-invasive marker in the tumor diagnosis and prognosis. Consequently, 
we examine radiomics extracted from the multi-resolution fractal representations of the tumor in 
classifying the molecular mutations of diffuse LGG non-invasively. The proposed radiomics in the 
decision-tree-based ensemble machine learning molecular prediction model confirm the efficacy 
of these fractal features in glioma prediction. Furthermore, this dissertation proposes a novel non-
invasive statistical model to classify and predict LGG molecular mutations based on radiomics and 
count-based genomics data. The performance results of the proposed statistical model indicate that 
fusing radiomics to count-based genomics improves the performance of mutations prediction. 
Furthermore, the radiomics-based glioblastoma survival prediction framework is proposed in this 
work. The survival prediction framework includes two survival prediction pipelines that combine 
different feature selection and regression approaches. The framework is evaluated using two recent 
widely used benchmark datasets from Brain Tumor Segmentation (BraTS) challenges in 2017 and 
 
 
2018. The first survival prediction pipeline offered the best overall performance in the 2017 
Challenge, and the second survival prediction pipeline offered the best performance using the 
validation dataset. In summary, in this work, we develop non-invasive computational and 
statistical models based on radiomics and genomics to investigate overall survival, tumor 
progression, and the molecular classification in diffuse gliomas. The methods discussed in our 
study are important steps towards a non-invasive approach to diffuse brain tumor classification, 
grading, and patient survival prediction that may be recommended prior to invasive tissue 
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Diffuse, or infiltrative, gliomas are types of Central Nervous System (CNS) brain tumors 
that account for 25.5% of primary brain and CNS tumors and 80% of malignant tumors [1]. 
Gliomas are considered the most malignant primary brain and CNS tumors. Gliomas originate 
from the supportive glial cells that consist of three major types: oligodendrocytes, astrocytes, and 
ependymal cells  [2]. Glial cells and neurons are the two major types of cells in the neural tissues. 
However, only glial cells can undergo cell division, and if the process of cell division is not 
carefully controlled and happens too fast, glioma forms and grows [3]. The broad range of glial 
cells causes different forms of gliomas: astrocytomas, oligodendrogliomas, and mixed gliomas 
such as oligoastrocytomas [4]. The 2007 World Health Organization (WHO) classification of 
gliomas was based on microscopic similarities with different cells of origin and their levels of 
malignancy. For example, Gliomas’ main types were classified based on their malignancy into 
grades II, III, and IV [5, 6]. The WHO grade II gliomas (low-grade gliomas) are generally 
infiltrating and have low mitotic activity (cell division and proliferation) and tend to progress to 
higher grades. The WHO grade III gliomas (high-grade gliomas) have a rapid mitotic activity and 
infiltrative capacity. The WHO grade IV gliomas (high-grade gliomas) have high mitotic activity, 
appear with necrosis, and usually are accompanied by a rapid progression and fatal outcome [5, 
7].  
Recently, studies have revealed the importance of the genetic elements in tumor formation 
and growth; such understanding may lead to greater diagnostic accuracy, as well as improved 
patient management and more accurate determination of prognosis and treatment response [8-11]. 
Major revision of diffuse gliomas of the 2007 CNS WHO classification have been introduced in 
the 2016 CNS WHO classification [12], which is established based on a combined phenotypic and 
genotypic classification, and the generation of “integrated” diagnoses. An updated classification 
of the diffuse lower-grade gliomas (LGG) is presented in the 2016 WHO Classification of Tumors 
of the CNS [12]. The new classification of the diffuse LGG (WHO Grade II and III gliomas) 
depends on the genetic driver mutations (IDH mutations, 1p/19q codeletion, and ATRX mutations), 
and their histological type (astrocytoma and oligodendroglioma) as illustrated in Figure 1. Note 
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that oligoastrocytomas are considered as not otherwise specified (NOS) categories unless there is 
no diagnostic molecular testing. This new classification correlates with patients’ treatment and 
survival. The histological types have different clinical behavior; oligodendroglioma tumors are 
associated with longer survival when compared to astrocytoma [13].  
 
 
Figure 1: The 2016 WHO Classification of the diffuse gliomas based on their histology 
and genetic mutations [12]. 
 
 
Isocitrate Dehydrogenase mutations, IDH1, and IDH2 have been found in gliomas [14-17]. 
Classifying gliomas based on their molecular profiling of IDH status (mutated vs. wildtype) creates 
clinically distinct groups. IDH wild-type gliomas behave aggressively when compared with the 
IDH mutant gliomas. As a result, patients with IDH mutant gliomas tend to have a better prognosis 
[18]. A 1p/19q codeletion is considered a molecular marker of oligodendroglioma and is associated 
with IDH mutation [19]. This genetic alteration happens when the short arm of chromosome 1 
(1p), and the long arm of chromosome 19 (19q) are deleted. The existence of 1p/19q codeletion in 




Using IDH mutation and 1p/19q codeletion, the diffuse LGG is classified into three groups 
[20]: 1p/19q codeletion with IDH mutant, 1p/19q non-codeletion with IDH mutant, and 1p/19q 
non-codeletion with IDH wild-type. ATRX is a somatic mutation in the Alpha-Thalassemia/mental 
Retardation syndrome, X-linked. This somatic mutation is reported in GBM [21]. This type of 
mutation frequently occurs in diffuse Astrocytoma and is associated with a significantly better 
prognosis [22, 23]. In addition, ATRX mutation has often occurred with IDH mutations and almost 
mutually exclusive with 1p/19q codeletion. Another molecular alteration that has a high prevalence 
of LGG is O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation [24]. 
Patients with a methylated MGMT promoter are associated with better overall survival [25, 26]. It 
has a better impact on overall survival if MGMT methylation is combined with IDH mutation and 
1p/19q codeletion [25]. Diffuse LGG is known for its heterogeneous characteristic that reveals 
variances in tumor biology. This heterogeneity can be seen through the histological types: 
astrocytoma, oligoastrocytoma, and oligodendroglioma [5, 12]. The heterogeneity can be 
characterized by magnetic resonance imaging (MRI) features [27-29], which suggests using MRI 
features as a non-invasive marker in tumor grading and classification [30-32]. 
Another diffuse infiltrative glioma is Glioblastoma multiforme (GBM). GBM accounts for 
14.6%  of primary brain and CNS tumors, 48.3% of primary malignant brain tumors, and 57.3% 
of gliomas [1]. GBM is staged as a WHO grade IV tumor [5] and arises from astrocytes glial cells. 
The extensive infiltrative growth pattern of Glioblastoma makes the curative treatment impossible 
and, hence, reduces the median survival rate to 15 - 16 months [33]. The naming “multiforme” in 
GBM emphasizes the heterogeneous nature of this type of glioma. The updated 2016 WHO 
classification of GBM is divided into GBM with IDH-wildtype, GBM with IDH-mutant, and NOS 
GBM, which is reserved for those tumors for which full IDH evaluation cannot be performed [34]. 
GBM IDH-wildtype accounts for ~90% of GBM, most frequently corresponds to primary (de 
novo) glioblastoma, and predominates in patients with a mean age of 61 years old. The median 
overall survival of GBM IDH-wildtype patients who are treated with surgery and radiotherapy is 
9.9 months and 15 months when treated with surgery and radio/chemotherapy. GBM IDH-mutant 
accounts for 10% and corresponds to secondary GBM (i.e. with a history of prior lower grade 
diffuse gliomas) in patients with a mean age of 48 years. The median overall survival of GBM 
IDH-mutant patients is 24 months when treated with surgery and radiotherapy and 31 months when 
treated with surgery and radio/chemotherapy. Glioblastomas heterogeneity may show significant 
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intertumoral (tumor by tumor) and intra-tumoral (within a tumor) heterogeneity. The tumor 
heterogeneity impacts the clinical outcome and overall survival [35, 36]. Thus, analyzing this 
heterogeneity is important for associating tumor phenotype with prognostic and predictive 
purposes [37].  
 
1.1 DISSERTATION GOALS AND PROBLEM STATEMENT 
 
In current radiology practice, radiomics have a critical role in disease diagnosis, 
monitoring, treatment planning, and personalized medicine [38, 39]. Radiomics acquisition is 
extracted from various radiological imaging modalities of the disease’s region of interest, which 
translates the radiographical images into useful data. Fusing crucial radiomics with clinical data in 
the proper machine/deep learning model may help to obtain a more comprehensive disease 
diagnosis and reliable early assessment of prognosis and treatment planning, and more 
personalized or precise medicine [40, 41]. Improving personalized treatment and precision 
medicine requires an accurate survival prediction, a fast and precise tumor detection, improved 
molecular grading and classification, and a detailed therapeutic response assessment of oncologic 
patients. Improvements in personalized medicine have succeeded as a consequence of advances in 
biologic and genomic technologies that rely on invasive methods of tissue sampling [42-44]. 
However, tissue sampling may also be associated with high cost, morbidity, and even mortality 
[45]. Also, in heterogeneous tumors such as glioblastomas, tissue sampling may not reflect the 
entire heterogeneity of the tumor. Consequently, developing alternative methods and non-
invasively analyzing patients’ survival-time prediction and classifying diffuse gliomas into 
subtypes using imaging features and machine learning techniques have emerged as vital and 
promising areas of research.  
This study introduces a non-invasive automatic gliomas molecular classification and 
grading prediction based on radiomics extracted from conventional magnetic resonance imaging 
and clinical data. Also, we develop a glioma grading model based on genomics count-based data 
and radiomics utilizing statistical modeling. Additionally, we introduce a radiomics guided non-
invasive gliomas clinical outcome of overall survival in patients with glioblastoma. 
The first goal of this dissertation addresses a non-invasive analysis of low-grade glioma 
grading and classification using radiomics features based on the 2016 WHO Classification of 
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Tumors of the CNS [12]. The new classification of the diffuse LGG depends on the genetic driver 
mutations (MGMT methylation, IDH mutation, 1p/19q codeletion, ATRX mutation, TERT 
mutation, and TP53 mutation). Because diffuse LGG is known for its heterogeneous characteristic, 
MRI features can be used to characterize this heterogeneity. The second goal of this dissertation is 
to propose a statistical radiogenomics model that utilizes both RNA sequencing (RNAseq) read 
counts data and radiomics for glioma molecular grading and prediction. The Negative Binomial 
(NB) distribution is fitted to RNAseq read counts to preserve the count-based nature of these data, 
and a log-linear regression modeling is fitted to the estimated mean of the NB distribution and 
linked with radiomics. Thus, a complete characterization radiogenomics prediction model is 
presented. The third goal of this dissertation is to obtain a radiomics-guided machine learning 
model for survival regression and prediction. In this work, we propose two representative survival 
prediction pipelines that combine different feature selection and regression approaches. The 
framework is evaluated using two widely used benchmark datasets from Brain Tumor 
Segmentation (BraTS) global challenges in 2017 and 2018.  
In general, alternative non-invasive radiomics-based machine learning models are critical 
in the body of research to analyze and predict glioma clinical outcomes prior to invasive tissue 
sampling. Although invasive tissue sampling is effective, non-invasive radiomics-based models 
may be preferred if these models offer competitive performance.  The efficacy of the radiomics-
based models proposed in this work indicates the potential of correlating radiomics (computed 
imaging features) with glioma molecular mutations types and overall survival. These models also 
identify candidates that may be considered potential predictive biomarkers of glioma molecular 
classification and overall survival. Furthermore, the recent interest in associating genomic 
phenotypes and radiomics has shifted the research towards utilizing both types of data in a single 




The main contributions of this dissertation are discussed as follows:  
1. Effective non-invasive analysis of diffuse low-grade gliomas grading and classification using 
radiomics features based on the 2016 WHO Classification of Tumors of the CNS 
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The 2016 WHO classification of diffuse LGGs heavily weighs molecular mutations 
classifying primary brain tumors with particular importance assigned to IDH mutation, 1p/19q 
codeletion, ATRX mutation, TERT mutations, and MGMT methylation. The second goal proposes 
and develops an imaging feature-based, computational machine learning model for diffuse LGGs 
classification and grading. Our model on diffuse LGG is largely able to predict the presence of the 
important molecular mutations as identified by WHO based on MR imaging features. Therefore, 
prediction of tumor aggressiveness (based on molecular mutations) may be achieved through non-
invasive imaging features as an adjunct to traditional visual morphologic diagnosis and invasive 
tissue sampling. The proposed model addresses possible overfitting, model instability, and the 
efficacy of fractal and multifractal textures on the performance of the proposed molecular mutation 
prediction models. To the best of our knowledge, this is the first study that addresses the potency 
of fractal and multi-resolution fractal features in molecular mutations prediction. The experimental 
demonstrations of the proposed molecular mutation prediction show promise when compared to 
different methods and models in the literature. The proposed methods are important steps towards 
non-invasive imaging classification of diffuse LGG based on molecular mutations prior to invasive 
tissue sampling. 
2. A novel RNA Sequencing and Radiomics statistical fusion model (radiogenomics-Negative 
Binomial) for Glioma Grading and Prediction  
In current radiology practice, radiomics plays a key role in disease diagnosis, monitoring, 
treatment planning, and grading [38, 39]. Radiomics is extracted from various radiological images 
of a targeted area of the disease. Fusing the important radiomics and genomics information in the 
computational machine learning (ML) model may help in achieving a comprehensive disease 
diagnosis, prognosis, and treatment plan. Consequently, such fusion may yield a personalized or 
precision medicine model [40, 41]. The rise of radiogenomics introduces more comprehensive and 
better profiling of personalized medicine for patients [27, 46-48]. Thus, associating between the 
radiomics phenotypes and underlying disease molecular mutations enhances clinical oncology care 
[49-51]. Different studies evaluate the association between glioma molecular subtypes and 
radiomics (e.g., tumor shape and size) [52-54] or between different forms of genomics (e.g., RNA 
sequencing (RNAseq) gene expression, protein expression, copy number, molecular mutations, or 
DNA methylation) and glioma subtypes [55-57]. These associations help to pave the way for ML-
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based classification of glioma molecular subtypes using radiomics [58-60], genomics [57, 61], or 
both [62-64].  
Conventional ML models do not adequately model the count-based nature of the RNA-
sequence data as these models are usually designed to work with data that has a normal 
distribution. In order to alleviate the lack of appropriate ML models, researchers propose to 
transform the RNAseq read-count data to approximate a normal distribution. The transformation 
to normal distribution allows the use of existing methods such as the nearest shrinkage method 
[65, 66] and Random Forest for classification. However, such transformation still removes the 
count-based nature of the RNAseq read counts data and, hence, lacks the ability to fully preserve 
the strong mean-variance relationship that is otherwise useful for glioma classification and 
prediction [67, 68]. In order to appropriately model the RNAseq read-count data, Negative 
Binomial (NB) and Poisson distributions are commonly used [69]. Poisson distribution is a single 
parameter distribution with its mean equals to its variance, which makes Poisson distribution rather 
restrictive. On the other hand, NB is similar to a Poisson distribution with an additional parameter 
called “dispersion” that allows the NB distribution to modify its variance without affecting the 
mean. On the other hand, existing works suggest the efficacy of using both genomics and radiomics 
data in the classification and prediction of different disease modality [70-73]. 
Consequently, this work proposes fusing RNAseq read counts data with radiomics in NB 
distribution to classify and predict glioma molecular mutations. Moreover, log-linear regression 
modeling is fitted to the estimated mean of the NB distribution and is linked with radiomics. We 
introduce this step to fuse the continuous radiomics data with the RNAseq count-based data 
without the need to transform RNAseq data into a normal distribution.  
Finally, we investigate the effect of using different numbers of differentially expressed 
genes from the count-based data as well as the gender factor by developing a gender-specific 
radiogenomics-NB model. Moreover, we compare our radiogenomics-NB model performance 
with that of different genomics and radiogenomics state-of-the-art methods in the literature. 
3. An efficient non-invasive machine learning for radiomics-based Glioblastoma survival 
regression and classification  
Different studies [74-76] have discussed different methods of predicting the survivability 
of patients with brain tumors. Pope et al. [74] use different subtype tumor volumes, the extent of 
resection, location, size, and other imaging features in order to assess the potential of these features 
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in predicting survival probabilities using the Kaplan-Meier method. Gutman et al. [75] use a 
comprehensive visual features set known as Visually AcceSAble Rembrandt Images (VASARI) 
in their study with glioblastoma patients. The authors have assessed the relationship between 
VASARI features and patients’ survival using multivariate Cox regression models and correlated 
these features with genetic alterations and molecular subtypes by using the Fisher exact test. Aerts 
et al. [76] predict survival using a multivariate Cox proportional hazards regression model by 
quantifying a large number of radiomics image features including shape and texture in computed 
tomography images of lung and head-and-neck cancer patients. Several of the survival prediction 
studies have been utilizing regression survival [77, 78] models such as the proportional hazard 
method. Lately, machine learning is replacing these proportional hazard methods to predict 
survival [79-81]. In this work, we utilize Random Forest and XGBoost in the survival regression 
and classification model. A feature-guided non-invasive machine learning approach is expected to 
benefit from known imaging features that are already proven effective to guide the efficacy of the 
proposed pipelines. Consequently, this work proposes a fully automated overall survival regression 
classification using imaging features extracted from the tumor volume of the raw structural MRI 
and three different texture characterizations of the tumor region. Finally, the framework is 
evaluated using two recent widely used benchmark datasets and global challenges in Brain Tumor 
Segmentation (BraTS) global challenges in 2017 and 2018, respectively. The overall contributions 





Table 1. Summary of the research findings related to the proposed methods. 
Chapter Dissertation goals Proposed Methods Novel Contributions 
3 Prediction and evaluation of 
tumor aggressiveness using 
molecular mutations through 
non-invasive fractal and 
multi-resolution fractal 
imaging features as adjunct 
marker.  
A XGBoost classification and 
prediction model using fractal and 
non-fractal features as input and 
molecular mutation information as 
the target output. 
Non-invasive molecular 
prediction model and efficacy 
validation of fractal features for 
glioma molecular prediction 
using traditional MRI data based 
on the latest 2016 WHO 
classification of LGG of the 
CNS. 
4 Glioma grading and 
prediction using joint 
statistical modeling of RNA 
sequencing and radiomics. 
A radiogenomics-Negative 
Binomial model that fuses 
radiomics (volumetric imaging 
features) with RNAseq (genes) for 
glioma grading and prediction. 
Negative Binomial distribution is 
proposed to fit RNAseq counts 
data. 
A novel RNA Sequencing and 
Radiomics statistical fusion 
model (radiogenomics-Negative 
Binomial) for Glioma grading 
and prediction, where a log-
linear regression model links 
between the estimated NB mean 
and radiomics.  
5 Glioma survival regression 
and classification using novel 
radiomics-based machine 
learning (ML) methods   
Two ML models for survival 
prediction are developed: 
a. A three-step feature 
selection along with RF 
regression classifier. 
b. A recursive feature 
selection along with XGBoost 
for classification step followed 
by a Cox regression along with 
three risk-based regression 
models.  
A novel framework for fully 
automated radiomics-based 
Glioblastoma survival 
prediction that provides 
competitive results when 
compared with the state-of-the-
art methods in BraTS 2017 and 
BraTS 2018 challenges and 




1.3 ORGANIZATION OF THE DISSERTATION  
 
The rest of the dissertation is organized as follows. Chapter 2 provides a background review 
on Gliomas’ survival and molecular mutation analysis and prediction using different sources of 
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features. Additionally, this chapter provides a background review on utilizing RNAseq read counts 
data in molecular mutations in diffuse LGG. Chapter 3 studies different molecular prediction 
models utilizing fractal and multi-resolution fractal texture features and other MR imaging features. 
The molecular models include the IDH, 1p/19q codeletion, MGMT, ATRX, and TERT prediction. 
In Chapter 4 we propose an RNA-radiomics (henceforth referred to as radiogenomics) -NB model 
for glioma grading and prediction. Our radiogenomics-NB model is developed based on 
differentially expressed RNAseq and selected radiomics features. Chapter 5 proposes a fully 
automated glioblastoma survival prediction framework based on MR imaging features. The survival 
prediction step includes two representative survival prediction pipelines that combine different 
feature selection and regression approaches. Chapter 6 provides the dissertation concluding remarks 









This chapter discusses the relevant previous work on glioma survival analysis and 
prediction, molecular mutations prediction in diffuse LGG based on MRI features, and molecular 
mutations classification based on RNAseq read counts data and MRI features. 
 
2.1 GLIOBLASTOMA SURVIVAL PREDICTION  
 
The World Health Organization (WHO) identifies Glioblastoma as a highly diffusive 
aggressive grade IV glioma, which is known for the presence of anaplastic glial cells, high mitotic 
activity, and dense cellularity, as well as an increase in microvascular proliferation [5, 82, 83]. The 
highly infiltrative growth pattern of Glioblastoma makes curative care difficult with a median 
survival time of less than 2-years [84]. Recently, research interests have been focused on replacing 
invasive methods of patients’ diagnosis and prognosis outcome with non-invasive methods [31, 
32, 49]. Glioblastoma heterogeneity and its implication on patients’ clinical outcomes [29, 36, 85] 
can be explored through radiology images such as MRI [31, 86, 87]. Thus, accurate detection and 
segmentation of different abnormal tumor tissues are essential in planning treatment therapy, 
diagnosis, grading, and survival prediction.  
Few works [74-76] have proposed different methods for assessing and predicting the 
survivability of patients with brain tumors using clinical data and imaging features. Pope et al. [74] 
evaluate and analyze the capability of different subtype tumor volumes, the extent of resection, 
location, size, and other imaging features in predicting the survivability of patients with grade III 
and grade IV GBM. The study reveals that patients’ age at diagnosis and Karnofsky Performance 
Status (KPS) shows a significant prognostic for both GBM grades. Additionally, a univariate Cox 
analysis shows that the tumor imaging features of non-contrast enhancing tumor, edema, satellites, 
and multifocality are statistically significant prognostic indicators in patients with GBM. Gutman 
et al. [75] conduct a comprehensive analysis of the visual features set known as Visually 
AcceSAble Rembrandt Images (VASARI) to study their association with GBM genetic mutations, 
molecular subtypes, and patient survival rate. The authors utilized four cardinal VASARI MR 
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imaging features along with a single measure of lesion size. Their analysis reveals that the volume 
of the contrast-enhancing tumor and the longest axis length of the GBM are statically associated 
with poor survival. The analysis also reveals that VASARI imaging features are associated with 
genetic alterations and molecular subtypes. However, the authors only address the visual features 
set and focus on the semi-quantitative measurements of the different tumor compartments and have 
not addressed other texture features. Aerts et al. [76] study the prognostic value of a large number 
of radiomics image features in computed tomography images of lung and head-and-neck cancer 
patients. These features include tumor image intensity, shape, texture, and multiscale wavelet. The 
authors perform a Kaplan-Meier survival analysis to study such an association. Additionally, the 
authors select the most important radiomics feature from each feature set, then utilize these four 
features in a multivariate Cox proportional hazards regression model for prediction of survival. 
Nicolasjilwan et al. [88] utilize clinical data, VASARI features, and genomics (represented by 
copy number variations) of GBM patients and combine these features into a stepwise multivariate 
Cox model for prediction of overall survival time. Prasanna et al. [89] extract radiomics texture 
features that characterize three tumor regions: enhanced tumor, peritumoral brain zone, and 
necrosis from MR images. These features are assessed for overall survival prediction. Itakura et 
al. [49] utilize quantitative MRI features that describe tumor histogram statistics, texture, edge 
sharpness, compactness, and roughness. Then the authors cluster the features into three MRI 
phenotypic imaging subtypes: pre-multifocal, spherical, and rim-enhancing tumor. The three 
distinct subtypes are then correlated with overall survival and associated with molecular pathways. 
The prevailing survival analysis and prediction studies have employed statistical survival 
regression techniques such as Kaplan-Meier and proportional hazard methods [76-78, 88]. 
Statistical survival analysis methods such as Kaplan-Meier and Cox regression analysis have 
difficulty capturing the complex relationship between the covariates and the outcome and suffer 
from cumulative incidence overestimation [90]. Recently, research has shifted towards replacing 
these statistical methods with improved machine learning methods because of the latter’s 
computational power, accuracy, and ability to employ a large number of different types of features. 
In this study, we hypothesize that radiomics imaging features along with the proposed 
machine learning techniques may offer superior efficacy in selecting important radiomics imaging 
features and predicting overall survival. In this study, we propose two fully automated survival 
prediction frameworks for patients with glioblastoma: overall survival regression using Random 
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Forest model [91] and overall survival classification and regression using Extreme Gradient 
Boosting (XGBoost) [92]. Radiomics imaging features are obtained from 1) raw structural MRI 
data, 2) Texton [93] characterization of the raw MRI, 3) and fractal and multi-resolution fractal 
representations of the raw MRI.  Fractal and multi-resolution fractal have shown their efficacy in 
brain tumor segmentation in prior studies [94-98]. The proposed framework is evaluated using two 
recent widely used benchmark datasets from Brain Tumor Segmentation (BraTS) global 
challenges in 2017 and 2018, respectively. Our results suggest that the proposed framework 
achieves better overall survival prediction performance compared to the state-of-the-art methods.  
 
2.2 MOLECULAR MUTATIONS IN DIFFUSE LOW-GRADE GLIOMAS  
 
The 2016 WHO classification of diffuse LGGs is based on molecular profiling to IDH 
mutation, 1p/19q codeletion, ATRX mutation, TERT mutations, and MGMT methylation. Such 
profiling requires invasive tumor tissue sampling However, non-invasive analysis of tumor 
aggressiveness using Imaging features is emerging to replace the invasive tissue sampling. An 
MGMT methylation prediction study by Kanas et al. [59] for patients with GBM reports the size 
of the tumor with respect to necrosis as one of the significant features. A GBM study conducted 
by Kanas et al.[59] proposes an MGMT prediction model using volumetric, morphological, and 
locational MR imaging features, respectively. The authors in [59] report the size of the tumor with 
respect to necrosis as one of the significant features. However, the entire process of the prediction 
model is not fully automated. Another study by Han et al. [99] where the authors use a bi-
directional convolutional recurrent neural network to predict MGMT methylation status. One 
major drawback of their study is that their model mainly utilizes imaging features that cannot be 
correlated with tumor biology. In an IDH prediction model by Yu et al. [100] on 110 patients with 
Grade II glioma, the authors use 110 imaging features and SVM to classify IDH status with Grade 
II glioma patients. However, the performance would reflect higher reliability of the performance 
of the IDH status prediction model if the dataset they use was more diverse with patients from 
Grade II and Grade III gliomas. A different study by Ding et al. [101] on 76 LGG patients utilizes 
MR imaging features along with MR spectroscopic data to predict IDH mutations using a binary 
logistic regression model. The authors achieved the best performance when utilizing MR 
spectroscopic data. A study by Akkus et al.[102] with LGG patients proposes 1p/19q codeletion 
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prediction using a convolutional neural network (CNN). In their study, the authors represent each 
patient’s MRI with only 3 MRI slices. The authors in Akkus et al. [102] do not consider the global 
information of the tumor since their dataset uses only 3 slices of the MRI sequence of each patient 
as input, not the whole volume of the tumor. A different recent study by van der Voort et al. [103] 
utilizes MR imaging features along with patients’ age and sex using an SVM classifier to predict 
1p/19q codeletion in LGG patients. The authors use 284 LGG patients for training and another 129 
LGG patients for testing. Their analysis reveals that the cranial/caudal location of the tumor is one 
of the most important features in predicting 1p/19q codeletion. Recently, Wang et al. [104] explore 
survival prediction and TERT mutations in 39 LGG (30 WT, and 9 Mutant). The authors propose 
a TERT prediction model using 24 imaging features selected using Principle Component Analysis 
(PCA) and classified using the Partial Least Squares (PLS). One major concern about their study 
is that the number of selected features (24 imaging features) is relatively high when compared to 
the dataset size (39 patients), which would increase the possibility of overfitting problems. In this 
work, we propose a fully automated computation prediction method of LGG molecular mutations 
utilizing radiomics imaging features. In our study, we utilize a more diverse dataset using Grade 
II and III, where significant and imaging features 1) are extracted from conventional MR imaging 
volumes that are clinically available and 2) are associated with overall survival and tumor biology. 
Additionally, we utilize fractal and multi-resolution fractal modeling. In this study, we hypothesize 
that the fractal and multi-resolution fractal modeling may be related to the underlying structure of 
molecular mutations. To the best of our knowledge, this is the first study that addresses the potency 
of fractal and multi-resolution fractal features in molecular mutations prediction. Several studies 
have shown the efficacy of fractal and multi-resolution fractal feature analysis for characterization, 
segmentation, and classification of the complex abnormal brain tissues in MRI [94, 97, 105, 106]. 
The spatial intensity distribution which is a basic property that characterizes medical images (such 
as MRI) have a degree of noise and randomness that allows the use of fractal and multi-resolution 
fractal texture modeling efficiently. The multi-resolution fractal modeling captures the randomly 
varying complex structure of the tumor texture on a different scale. Few studies have shown an 
association between different types of imaging features such as the grey-level co-occurrence 
matrix (GLCM) for texture, volume and area related features, and intensity-based features to the 
tumor classification [107-110]. While GLCM features may capture the grey-level spatial variation 
in an image, these deterministic features may not be effective in the analysis of the random surface 
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structure variation of abnormal tumor tissues in MRI. Wavelet features, on the other hand, examine 
the intensity variation of the tumor tissues in different image resolutions [111, 112]. In comparison, 
the multi-resolution fractal modeling mathematically combines the capabilities of regular texture 
analysis (e.g., GLCM) and multi-resolution analysis (e.g., wavelets) and, hence, may capture the 
randomly varying complex structure of the tumor tissue texture at different scales. The spatial 
intensity distributions of abnormal brain tissues in MRI have a degree of randomness that is 
amenable to fractal and multi-resolution fractal texture modeling. 
 
2.3 RNA SEQUENCING AND RADIOMICS  
 
RNAseq is a new technology that employs next-generation sequencing technology (NGS). 
RNAseq has developed as a novel technique to replace microarrays to measure gene expression. 
In RNAseq, the gene expression level is quantified by counting the number of times the RNAseq 
reads map (i.e. align) to one gene [113]. One of the major drawbacks of microarrays is background 
noise. RNAseq starts with isolating RNA from the organism, then converts RNA fragments to 
complementary DNA (cDNA), then prepares the sequencing library, and finally sequences the 
cDNA using NGS platform. RNAseq is a very sensitive technique that provides high resolution 
and a thorough understanding of the transcriptome and has revealed many novel gene structures.  
RNAseq distribution requires an appropriate model that adapts and preserves the nature of 
RNAseq read counts data, and such classification models that preserve the nature of RNAseq are 
lacking in the traditional ML literature. The NB distribution is an appropriate choice to model such 
discrete read counts data [69]. Even though traditional ML tools that are developed based on NB 
are lacking, the choice of using NB distribution in differential gene expression and RNAseq 
analysis has been adapted by different studies in literature such as in EdgeR [114-116], DESeq 
[117], and NBPSeq [118]. In EdgeR [114-116], the authors estimate the NB dispersion parameter 
using a quantile-adjusted conditional maximum likelihood estimator assuming a common 
dispersion between the different genes and replicates. However, a common dispersion between the 
different genes is generally not true. Therefore, reference [115] defines a weighted conditional log-
likelihood as a combination of “individual” and weighted “common” likelihoods. The "common" 
likelihood assumes all genes have a common dispersion value. The "individual" likelihood is 
estimated by conditioning on the sum of counts of a gene for each class.  
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An example of a count-based classifier that fits NB distribution is the Negative Binomial 
Linear Discriminant Analysis (NBLDA). NBLDA is a well-known classifier that is developed by 
fitting NB to RNAseq and the mean and dispersion parameter are estimated from the RNAseq data 
[119].  In the NBLDA method, the dispersion parameter is estimated using the shrinkage estimator 
that is proposed by Yu et al. [120]. A different type of classifier, known as VoomNSC, is developed 
based on the transformed count data. VoomNSC is a combination of voom (an acronym for mean-
variance modeling at the observational level) transformation [65] and the nearest shrunken 
centroids classifier (NSC) [121]. Voom is designed as follows: first RNAseq read counts are 
transformed as the log-counts per million (log CPM). Then, a relationship between the square-
root-standard-deviations and the mean of the log-count. Then, a precision weight (i.e., the inverse 
of the variance) of each sample is estimated. The estimated weights and the log-counts are used to 
build the NSC classifier. In NSC, a soft-thresholding shrinkage method is used to shrink each 
weighted difference score between a particular gene centroid and the overall centroid toward zero. 
Then, the updated weighted difference is used to update the weighted centroid for each remaining 
gene (i.e. important genes). In the prediction step, the updated weighted centroids of the important 







PREDICTION OF MOLECULAR MUTATIONS IN DIFFUSE LOW-GRADE GLIOMAS 
USING RADIOMICS  
 
3.1 CHAPTER OVERVIEW 
 
The 2016 WHO classification of CNS presents a major restructuring of diffuse gliomas. 
The updated classification of diffuse gliomas group tumors based on the shared genetic driver 
mutations, in addition to their growth pattern and behavior. Currently, the status of molecular 
mutations such as IDH mutations, ATRX, mutation, TERT mutation, and 1p/19 codeletion is 
determined by obtaining tissue samples that represent viable regions of the tumor with elevated 
proliferation and neovascularization [122].  
A shift into developing alternative methods to non-invasively classify diffuse LGG into its 
different subtypes has inspired different research groups to employ the developing field of 
radiomics and machine learning techniques. In this chapter, we address diffuse LGG grading and 
classification prediction based on molecular mutations using imaging features that are extracted 
from multimodality raw MRI sequences (T1, T1Gd, T2 FLAIR, and T2) of the anatomically 
depicted tumor volume and texture representations of the tumor MRI sequences. The extracted 
features describe the multi-resolution fractal features, texture features, volumetric, and area-based 
characteristics. In this study, different molecular (IDH, 1p/19q codeletion, ATRX, and TERT), and 
MGMT methylation prediction models are introduced. In addition, our study investigates the 
efficacy of our novel texture features the fractal and multi-resolution fractal modeling on the 
performance of the non-invasive prediction of molecular mutation in LGG. 
Several studies have shown the efficacy of fractal and multi-resolution fractal feature 
analysis for characterization, segmentation, and classification of complex abnormal brain tissues in 
MRI [94, 97, 105, 106]. Consequently, in this study, we hypothesize that the fractal and multi-
resolution fractal modeling may relate to the underlying structure of molecular mutations. To the 
best of our knowledge, this is the first study that addresses the potency of fractal and multi-








In this study, we use a total of 108 pre-operative LGG patients described in [123-125]. Four 
sequences of the MRI are provided with the dataset: pre-contrast T1-weighted (T1), post-contrast 
T1-weighted (T1Gd), T2-weighted (T2), and T2 Fluid Attenuated Inversion Recovery (FLAIR). 
These scans are skull-stripped, re-sampled to 1 mm3 resolution, and co-registered to the T1 
template. The dataset provides the segmented sub-regions of the LGG: Gadolinium enhanced tumor 
(ET), the peritumoral edema (ED), and the necrosis along with non-contrast enhancing tumor 
(NCR/NET). Molecular alterations (IDH mutation, 1p/19q codeletion, ATRX, and TERT mutation), 
grade (II and III), and clinical data are downloaded from the Genomic Data Commons Data Portal 
(https://portal.gdc.cancer.gov/). Clinical data are de-identified by the Health Insurance Portability 
and Accountability Act of 1996 (HIPAA). The distribution of the data is as follows: (i) IDH 
mutation: 85 Mutant (of which 27 cases are co-deleted) and 23 wildtype (WT), (ii) 1p/19q 
codeletion: 27 codeletion and 81 non-codeletion, (iii) ATRX status: 43 Mutant and 65 WT, (iv) 
TERT status: 46 Mutant and 62 WT, and (v) O6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation: 91 methylated and 14 un-methylated. The patient age range of the at the time 






Figure 2. An overview of the proposed LGG Molecular Mutation prediction Model. 
 
 
3.2.2 METHODOLOGY  
 
In this study, we introduce different molecular prediction models based on fractal and multi-
resolution fractal texture features and other MR imaging features. These molecular models include 
the IDH, 1p/19q codeletion, MGMT, ATRX, and TERT prediction. A classic way to avoid 
overfitting is to divide the dataset into training, validation, and testing datasets [126]. The dataset 
is randomly partitioned into training (75% of the entire dataset = 81 cases) and testing (25% of the 
entire dataset = 27 cases) subsets. A balanced distribution of the target molecular mutation is 
ensured in the training and testing sets in each molecular prediction model. The features are 
extracted from multimodality MRI sequences of the tumor volume in the training partition. Then, 
a recursive feature selection is performed to select the number of features and is validated with 
Leave-One-Out Cross-Validation (LOOCV). The selected features are then trained using an 
Extreme Gradient Boosting (XGBoost) method along with LOOCV. Then, a prediction 




Furthermore, we study the efficacy of fractal and multi-resolution fractal texture features 
(e.g., piecewise-triangular prism surface area (PTPSA), multi-resolution fractional Brownian 
motion (mBm), and Holder Exponent (HE)) extracted from tumor volumes on the performance of 
the molecular mutation prediction models. Figure 2 shows the overall pipeline of the proposed 
LGG-XGBoost prediction model for different molecular mutations in LGG.  
 
3.2.3 FEATURE EXTRACTION  
 
In this study, around 680 features are extracted to represent texture, volume, and area of the 
tumor and its sub-regions (edema, enhanced tumor, and necrosis). These features include 41 texture 
features [127] extracted from the tumor volume in raw MRI (T1Gd, T2, and FLAIR) sequences and 
an additional three different texture characterizations of the tumor region. The three texture 
characterizations are as follows:  
• fractal characterization using our PTPSA[96]  modeling,  
• multi-resolution mBm[97] modeling,  
• and the characterization Holder Exponent (HE) [128, 129] modeling of the tumor region.  
The computational algorithm of the PTPSA, mBm, and the HE is found in [96, 97, 130]. 
The 41 texture features are: global variance, skewness, kurtosis, energy, contrast, correlation, 
homogeneity, variance, sum average, entropy, short-run emphasis, long-run emphasis, gray-level 
non-uniformity, run-length non-uniformity, run percentage, low gray-level run emphasis, high 
gray-level run emphasis, short-run low gray-level emphasis, short-run high gray-level emphasis, 
long-run low gray-level emphasis, long-run high gray-level emphasis, gray-level variance, run-
length variance, small zone emphasis, large zone emphasis, gray-level non-uniformity, zone-size 
non-uniformity, zone percentage, low gray-level zone emphasis, high gray-level zone emphasis, 
small zone low gray-level emphasis, small zone high gray-level emphasis, large zone low gray-
level emphasis, large zone high gray-level emphasis, gray-level variance, zone-size variance, 
coarseness, contrast, busyness, complexity, and strength. 
Furthermore, six histogram-based statistics (mean, variance, skewness, kurtosis, energy, 
and entropy) features are also extracted from the different tumor sub-regions (edema, enhanced 
tumor, and necrosis), respectively. 
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In addition, we extracted 12 volumetric features: the volume of the whole tumor, the volume 
of the whole tumor with respect to the brain, the volume of sub-regions (edema, enhanced tumor, 
and necrosis) divided by the whole tumor, the volume of sub-regions (edema, enhanced tumor, and 
necrosis) divided by the brain, the volumes of the enhanced tumor and necrosis divided by the 
edema, the summation of the volume of the edema and enhanced tumor, the volume of the edema 
divided by the summation of the volume of enhanced tumor and necrosis, and the volume of the 
necrosis divided by the summation of the volume of the edema and enhanced tumor. Finally, nine-
volume properties (area, bounding box, centroid, perimeter, major axis length, minor axis length, 
eccentricity, orientation, solidity, and extent) are extracted from the tumor volume and from three 
viewpoints (x, y, and z-axes) of the tumor and its sub-regions (edema, enhanced tumor, and 
necrosis).  
Texture features are analyzed using MATLAB-based software developed by Vallières et 
al.[127]. Fractal characterization, multi-resolution fractal characterization, HE characterization, and 
volumetric features are analyzed using MATLAB-based in-house software. 
 
3.2.4 MOLECULAR MUTATION PREDICTION MODEL AND FEATURE 
SELECTION 
 
The molecular mutation prediction model is performed on the training set using nested 
LOOCV to avoid an optimistic performance estimate. Recursive feature selection is performed in 
the inner loop to find the optimum features set. The LOO cross-validated performance of the 
molecular mutation prediction model is estimated in the outer loop. The molecular mutation 
prediction model is performed using the R statistical packages Caret and XGBoost (www.r-
project.org). 
Recursive feature selection (RFS) is implemented by first fitting a Random Forest (RF) 
model to all features. Each feature is ranked by its importance, and the least important features are 
removed from the current feature set. Then, this step is repeated recursively until the optimum 
features set that has the best performance is reached. In our implementation of recursive feature 
selection, the number of features in the features’ sets are 2, 3, 5, 7, 9, 11, 13, and 15 features. In 
addition, the best performance is determined by maximizing the area under the receiver operating 
characteristic (ROC) metric. The feature set that provides the combination of features that maximize 
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the area under the ROC (AUC) is chosen for training in the prediction model. Using recursive 
feature selection, the maximum number of selected features is fifteen so that the training samples 
(eighty-one cases) is at least 5 times the number of features to reduce model overfitting.  
In our study, XGBoost is utilized as a classification and prediction model using the 
optimum features set as input and molecular mutation information as the target output. XGBoost 
[131] is an advanced tree boosting supervised machine learning technique that is effective in 
handling imbalanced datasets. XGBoost is widely used in classification and regression tasks. For 
a given dataset 𝐷𝐷 with s samples and m features 𝐷𝐷 = {(𝑥𝑥𝑖𝑖,𝑦𝑦𝑖𝑖)}(|𝐷𝐷| = 𝑠𝑠, 𝑥𝑥𝑖𝑖 ∈ ℝ𝑚𝑚,𝑦𝑦𝑖𝑖 ∈ ℝ ), a tree 
ensemble model uses K additive functions to predict the output as follows, 
 
𝑦𝑦𝚤𝚤� = ∑ 𝑓𝑓𝑘𝑘(𝑥𝑥𝑖𝑖)𝐾𝐾𝑘𝑘=1 ,𝑓𝑓𝑘𝑘 ∈ 𝐹𝐹,      (1) 
 
where 𝑥𝑥𝑖𝑖 is the feature/input vector, 𝑦𝑦𝑖𝑖 is the target/output variable, and 𝑓𝑓(𝑥𝑥) is a function in the 
functional space 𝐹𝐹, and 𝐹𝐹 is a set of all possible classification and regression trees. One of the major 
advantages of using XGBoost is that XGBoost provides L1 and L2 regularization. L1 regularization 
handles sparsity, whereas L2 regularization reduces overfitting. In addition, we choose XGBoost 
because it is known for handling an imbalanced dataset.  A detailed mathematical derivation of the 
XGBoost algorithm is found in Chen et al. [131]. The final molecular mutation prediction model 
(that is used for the testing set) is obtained by fitting the optimum features set that maximizes 
performance in the inner loop (over all the outer cross-validation loops). Note, if more than one 
feature sets maximize inner loop performance, the common features between the features’ sets are 
used. The prediction performance of the final molecular mutation model is tested using the paired 
testing sets (partitions).  
Finally, in order to study the efficacy of fractal and multi-resolution fractal texture features 
used in this study (e.g., PTPSA, mBm, and Holder Exponent) on the performance of the proposed 
prediction models as shown in Figure 2, we perform molecular prediction analyses with and 
without these texture features, respectively. The entire process in Figure 2 is repeated n times 
independently with n different training/testing set pairs. The n number of repetitions is a random 




3.2.5 MOLECULAR MODELS EVALUATION 
 
The molecular models are validated using separate testing sets, and the prediction 
performance (test performance) of the trained XGBoost model is estimated using AUC, sensitivity, 
and specificity. After n times of independent repetitions, the ANOVA test is used to compare the 
difference in the prediction performance between two models with and without the fractal and 
multi-resolution fractal texture in the prediction models. In addition, ANOVA is used to analyze 
the significant association between features and the different molecular mutations. The survival 
groups that are formed using the significant features are compared using Kaplan-Meier curves and 
the log-rank test. The hazard ratio of features is determined using the Cox proportional hazards 
model and assessed using the likelihood-ratio test. Finally, the evaluation step for Survival is 
conducted using R statistical packages. 
 
3.3 EXPERIMENTAL RESULTS 
 
Around 680 imaging features are extracted from multimodality MRI sequences. Recursive 
feature selection is used to find the optimum number of significant features for each molecular 
mutation prediction model. Our analyses of the different prediction models are repeated 
independently n times with different training and testing pairs (partitions). Table 2 displays the 
number of repetitions n, LOOCV performance, and the test performance of the different prediction 
models when including/removing texture characterization of the fractal and multi-resolution fractal 
of PTPSA, mBm, and Holder Exponent characterization.  
 
3.3.1 MGMT METHYLATION MODEL 
 
The most frequent features that are selected are the necrosis width in the Z planar, the 
histogram entropy of the mBm characterization on the whole tumor, and size ratio between the 
enhanced tumor and the necrosis. The necrosis width in the Z planar, the histogram entropy of the 
mBm characterization on the whole tumor features are significantly (ANOVA test, p-value < 0.05) 
associated with methylated MGMT, whereas the size ratio between enhanced tumor and necrosis 








Figure 3. MGMT methylation models.  a) Distribution of the most selected features in 
discriminating MGMT mutated and WT, and b) MGMT prediction model performance using the 
train and test partitions with and without fractal texture features. Error bars represent standard 





The LOOCV performance and the prediction performance on the testing set for predicting 
the MGMT methylation status using imaging features are illustrated in Table 2 and Figure 3b. The 
prediction performance using the test partitions achieves an AUC, a sensitivity, and a specificity 
of 0. 0.83±0.04, 0.93±0.05, and 0.73±0.13, respectively.  
Removal of our fractal and multi-resolution fractal features from the MGMT methylation 
prediction model has an effect on the prediction performance on the testing set. AUC and 
specificity drop significantly (ANOVA test, p-value = 0.003, and 0.01, respectively) when the 
fractal features are removed  (Figure 3b). 
 
 
Table 2. LOO cross-validated performance of the outer-loop, and the predictive/test 






With fractal & multi-resolution 
fractal features 
Without fractal & multi-resolution 
fractal features 
AUC. Sens. Spec. AUC. Sens. Spec. 
MGMT 
Methylation 
11 0.86±0.03 0.88±0.02 0.80±0.09 0.87±0.04 0.90±0.02 0.66±0.10 
IDH mutation 13 0.85±0.04 0.90±0.03 0.75±0.05 0.79±0.07 0.89±0.08 0.75±0.07 
1p/19q 
codeletion 
15 0.83±0.03 0.78±0.08 0.83±0.03 0.80±0.05 0.63±0.08 0.87±0.02 
ATRX 
mutation 
10 0.77±0.06 0.62±0.09 0.80±0.03 0.80±0.04 0.77±0.06 0.76±0.03 
TERT 14 0.82±0.04 0.70±0.06 0.83±0.04 0.82±0.04 0.82±0.04 0.76±0.05 
Prediction/test 
Performance 
       
MGMT 
Methylation 
11 0.83±0.04 0.93±0.05 0.73±0.13 0.70±0.12 0.90±0.07 0.50±0.24 
IDH mutation 13 0.84±0.03 0.90±0.06 0.79±0.09 0.75±0.07 0.83±0.11 0.66±0.18 
1p/19q 
codeletion 
15 0.80±0.04 0.75±0.08 0.85±0.06 0.75±0.07 0.67±0.12 0.84±0.10 
ATRX 
mutation 
10 0.70±0.09 0.69±0.06 0.83±0.10 0.66±0.10 0.65±0.16 0.68±0.18 




3.3.2 IDH MUTATION MODEL 
 
Our analysis reveals that the tumor correlation, the vertical orientation of edema major axis 
(the angle between the edema major axis and the vertical axis), the size ratio between the enhanced 
tumor and the necrosis, and the complexity of the holder exponent of the tumor are among the 
most frequently selected features to predict IDH-mutated status in LGG. Higher values of the 
complexity of holder exponent of the tumor, the size ratio between the enhanced tumor and the 
necrosis, and higher values of the vertical orientation of edema major axis associate significantly 
(ANOVA test, p-value < 0.005) with WT IDH status, whereas the tumor correlation associates 
significantly (ANOVA test, p-value < 0.005) with mutated IDH status as illustrated in  Figure 4a. 
Figure 4b shows the clustering of IDH status using the most frequent features in  Figure 4a. The 
clustering between the mutated IDH and WT IDH is demonstrated using t-Distributed Stochastic 
Neighbor Embedding (tSNE) [132]. 
In addition, the tumor correlation, the vertical orientation of edema major axis, and the 
complexity of holder exponent of the tumor features carry a hazard ratio [HR] of 0.562 (95% CI, 
0.381-0.828), 2.655 (95% CI, 1.617-4.36), and 1.553 (95% CI, 1.165-2.07) with likelihood ratio 
test p-value = 0.005, 0.0001, 0.008, respectively. Because these features are continuous features, 
the HRs interpolate as follows: the risk of death increases (or decreases if HR<1) by (HR-1) ×100% 
for every 1-standard deviation increase in that feature. The LOOCV and the test performance of 
the proposed IDH models are illustrated in Table 2. The prediction performance using the testing 
partitions achieves an AUC, sensitivity, and specificity of 0.84±0.03, 0.90±0.06, and 0.79±0.09, 
respectively. Note that the AUC and specificity of the IDH status prediction model drop 
significantly to 0.75±0.07 and 0.66±0.18 (ANOVA test, p = 0.0001 and p = 0.028, respectively) 
after removing features extracted from texture extracted from fractal and the multi-resolution 






Figure 4. IDH models.  a) Distribution of the most selected features in discriminating 
among IDH mutated and WT cases in LGG, b) 2-D t-Distributed Stochastic Neighbor Embedding 
(t-SNE) visualization using only the 4 features in A, and c) Performance comparison of IDH 
prediction model using the train and test partitions with and without fractal features. Error bars 












3.3.3 1P/19Q CODELETION MODEL 
 
The necrosis upper-left bounding box location, the histogram entropy of mBm 
characterization of the whole tumor, and the horizontal coordinate of necrosis centroid are the most 
frequent optimum features that are selected in our proposed 1p/19q codeletion models. These three 
features show significance (ANOVA test, p-value < 0.0001) associated with the existence of the 
1p/19q codeletion. Our analysis shows frontal tumors are associated significantly (ANOVA test, 
p-value < 0.0001) with 1p/19q codeletion mutations (Figure 5.a). The performance of the proposed 
codeletion prediction LOOCV model is illustrated in Table 2. The 1p/19q codeletion performance 
using the test partitions achieves an AUC of 0.80±0.04, a sensitivity of 0.75±0.08, and a specificity 
of 0.85±0.06. In addition, the efficacy of our fractal and multi-resolution fractal texture features 
on the performance of the codeletion prediction model is significant as shown in Figure 5b and 
Table 2. The AUC and the sensitivity of the codeletion prediction model drop significantly 
(ANOVA test, p-value of 0.024 and 0.029, respectively) after removing features extracted from 
our fractal and multi-resolution fractal features in the 1p/19q codeletion prediction model to 
0.75±0.07 and 0.67±0.12 (without fractal features). Figure 5c illustrates the location of the 
centroid and the upper-left bounding box of the necrosis. The histogram entropy of mBm of the 
tumor volume offers HR of 0.59 per standard deviation (95% CI, 0.35-0.97) with a likelihood ratio 









Figure 5. 1p/19q codeletion models. a) Distribution of the most selected features in 
discriminating 1p/19q codeletion and non-codeletion, b) Performance comparison of codeletion 
classifier models using the train and test partitions with and without fractal features. c) Example of 
FLAIR images illustrates the location of the necrosis centroid and the upper-left location of the 
necrosis bounding-box. Error bars represent 2 standard deviations. The asterisk * illustrates the 






Figure 5. (continued) 
 
 
3.3.4 ATRX MUTATION MODEL 
 
The information content of correlation and the histogram mean of the tumor volume of the 
most frequently selected features are employed in the XGBoost model to train and predict ATRX 
status. The distribution of the most frequent features is illustrated in Figure 6.a. Higher values of 
information of correlation are associated significantly (ANOVA test, p-value < 0.001) with ATRX 
wildtype, whereas higher values of histogram mean are associated significantly (ANOVA test, p-
value < 0.001) with mutated ATRX. The ATRX prediction model achieves prediction performance 
of an AUC of 0.70±0.09, a sensitivity of 0.70±0.06, and a specificity of 0.83±0.10 using the test 
partitions. Removing features extracted from our fractal and multi-resolution fractal modeling from 
the ATRX prediction model has a significance specificity drop to 0.68±0.18 performance of the 












Figure 6. Distribution of the most selected feature in discriminating a) mutated ATRX and 
WT, b) Performance comparison of ATRX classifier models using the train and test partitions with 
and without fractal features. Error bars represent 2 standard deviations. The asterisk * illustrates the 













3.3.5 TERT MUTATION MODEL 
 
After reviewing the most frequently selected imaging features of the TERT mutation 
prediction model, we notice that the information content of correlation of the tumor volume, the 
edema upper-left bounding box location, and the inverse difference moment of HE characterization 
of tumor volume are the most frequently selected features (Figure 6c). The inverse difference 
moment of HE characterization of tumor volume offers HR of 0.612 per standard deviation (95% 
CI, 0.405-0.924) with a likelihood ratio test p-value = 0.027. The TERT prediction models’ 
performances are illustrated in Table 2. The TERT prediction performance using the test partitions 
achieves an AUC of 0.82±0.04, a sensitivity of 0.77±0.12, and a specificity of 0.86±0.09, 
respectively. Removing our fractal and multi-resolution fractal texture modeling has no significant 
effect on the TERT performance of prediction models when using the test partitions as shown in 
Table 2.  
 
3.4 DISCUSSIONS   
 
The 2016 WHO classification of diffuse LGGs heavily weighs molecular mutations 
classifying primary brain tumors with particular importance assigned to IDH mutation, 1p/19q 
codeletion, ATRX mutation, TERT mutations, and MGMT methylation. Our study on diffuse LGG 
is largely able to predict the presence of these important molecular mutations based on MR 
imaging features. Therefore, prediction of tumor aggressiveness (based on molecular mutations) 
may be achieved through non-invasive imaging features as an adjunct to traditional visual 
morphologic diagnosis and invasive tissue sampling. 
In this work, the number of originally extracted imaging features (six hundred eighty 
features) is higher than the number of samples (eighty-one cases) in the training dataset, which 
may cause overfitting. To address possible overfitting, we implement feature selection in the 
training model that offers a maximum of fifteen selected features. Figure 7 illustrates the effects 
of the number of features on the cross-validated performance of the different mutation prediction 
models. The average AUC performances and the standard error of the different prediction models 
improve when the number of features is greater than 9. Note that the standard error mostly plateaus 
when the number of features varies between 9-15 (standard error reflects instability).   
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For the fractal and multifractal texture model in Table 2, the AUC predictive performance 
of MGMT, 1p/19q codeletion, and ATRX models drop to 0.83±0.04, 0.80±0.04, and 0.70±0.09, 
respectively. This statistically non-significant drop in performance (ANOVA test, p-value = 
0.076, p-value = 0.073, and p-value = 0.071 respectively) when compared to their AUC cross-
validated performance, may suggest minimal overfitting for these models. The AUC predictive 
performances of IDH and TERT models are almost comparable to their cross-validated 
performance as shown in Table 2 that suggests there is no overfitting in these two models.  
For the non-fractal models in Table 2,  the AUC predictive performance of IDH, 1p/19q 
codeletion, and TERT models drops to 0.75±0.07, 0.75±0.07, and 0.78±0.07 respectively. This 
statistically non-significant drop (ANOVA test, p-value = 0.182, p-value = 0.056, and p-value = 
0.062 respectively) when compared to their AUC cross-validated performance, may suggest 
minimal overfitting for these models. However, the poor predictive performances of the non-
fractal MGMT and non-fractal ATRX models when compared with their non-fractal cross-
validated performances are a sign of overfitting.   
Note optimally chosen features in the non-fractal models are not selected by simply 
replacing the fractal features with alternate features (or by using the same number of predictors as 
in the fractal models). In each mutation model (fractal or non-fractal), RFS (and thus selecting 
optimally chosen features) is performed independently. In our implementation of RFS for fractal or 
non-fractal models, the possible number of features in the features’ sets could be 2, 3, 5, 7, 9, 11, 
13, and 15, respectively. The maximum number of selected features is set to 15 such that the training 
samples (81 cases) are at least 5 times the number of features to reduce the possibility of model 
overfitting.    
Finally, we compare the performances of our prediction models with a list of state-of-the-
art studies as illustrated in Table 3. However, a direct comparison between the performances of 
our proposed models and these studies may not be relevant because of the different datasets. 







Figure 7. The effect of number of features on cross-validated performance of the different 
mutation models.  a) MGMT prediction model, b) IDH prediction model, c) 1p/19q codeletion 
prediction model, d) ATRX prediction model, and e) TERT prediction model. The y axis represents 
mean AUC of every feature set which is computed from all independent n repetitions, and error bars 





















Figure 8. The effect of thresholding a) the size ratio between the enhanced tumor and 
necrosis, b) tumor correlation, and c) vertical orientation of edema major axis around the median. 





Figure 8. (continued) 
 
 
Our study on MGMT methylation prediction shows that MGMT methylation correlates 
with high values of fractal texture features such as histogram entropy of mBm for tumor volume. 
Entropy measures randomness or uncertainty in the tumor. The analysis reveals that high 
histogram entropy of mBm associates with the less aggressive methylated MGMT status and 
carries HR of 0.579 per standard deviation (95%CI, 0.345, 0.969) with likelihood ratio test p-value 
= 0.035. The study further shows that the size ratio between enhanced tumor and necrosis 
correlates significantly with un-methylated MGMT, which indicates that the higher the aggressive 
MGMT un-methylated LGG, the higher the values of the size ratio.  
The MGMT methylation prediction study by Kanas et al. [59] for patients with GBM 
reports the size of the tumor with respect to necrosis as one of the significant features. Our analysis 
shows that removing the texture features such as fractal and the multi-resolution fractal (of PTPSA, 
mBm, and Holder Exponent) characterization is significant on the AUC and specificity 
performance of the MGMT methylation model. The GBM study conducted by Kanas et al. [59] 
(Table 3) proposes an MGMT prediction model using volumetric, morphological, and locational 
MR imaging features, respectively. In our study, we use texture features and volumetric features. 
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Moreover, the entire process of the prediction model in our current study including feature 
extraction is automated, unlike the proposed work by Kanas et al. [59]. In another study by Han et 
al. [99] (Table 3), the authors use a bi-directional convolutional recurrent neural network to predict 
MGMT methylation status. A major difference between our MGMT prediction model and the 
method proposed by Han et al. [99] is that our model mainly utilizes quantitative imaging features 
that can be correlated with tumor biology.  
In addition, our IDH mutation prediction model indicates that the tumor correlation 
associates significantly with mutated IDH and offers HR of 0.562 per standard deviation with a 
likelihood ratio test p-value =0.005. In addition, our analysis shows that the complexity of HE of 
enhanced tumor associates significantly with WT IDH status with HR of 1.553 per standard 
deviation with a likelihood ratio test p-value =0.008. Complexity is related to the visual 
information content and the shape of the object. Texture with higher information content and with 
a large number of edges is considered complex [133]. This outcome is in agreement with another 
glioma study by Wang et al. [134] which reports that the enhancement patterns predict the 
prognosis in IDH1 mutations in Anaplastic gliomas. Our analysis also shows that the size ratio 
between enhanced tumor and necrosis is a significant predictive feature of the IDH status. This 
feature is also a significant predictor of MGMT status, which can be explained by the fact that 
MGMT methylation is associated with IDH status as reported by different studies [14, 135].  
The IDH prediction model by Yu et al. [100]  (Table 3) uses 110 imaging features and 
SVM for Grade II glioma. Even though the dataset we use in the IDH mutation prediction is not 
the same as the dataset used by Yu et al. [100], the dataset used in our study is more diverse with 
data from both Grade II and III, and this reflects higher reliability of the performance of the IDH 
status prediction model.  
Furthermore, our study on the 1p/19q codeletion prediction model indicates that the 
location of the upper-left necrosis bounding box and horizontal coordinate of the necrosis centroid 
(illustrated in Figure 5c) are among the most predictive features. This outcome is in agreement 
with different studies [136-138] which report that gliomas with 1p/19q codeletion are associated 
with the tumor location. In addition, our analysis shows that higher values of histogram entropy of 
mBm texture of tumor volume associate significantly with the existence of 1p/19q codeletion. 
Moreover, our analysis reveals that removing the texture representation of fractal and multi-
resolution fractal from the 1p/19q codeletion prediction model decreases the AUC and specificity 
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significantly. The test prediction performance of the 1p/19q codeletion prediction model drops 
(after removing the fractal features). A study by Akkus et al. [102] (Table 3) with LGG patients 
(where each patient has 3 MRI slices) proposes 1p/19q codeletion prediction using a convolutional 
neural network (CNN). Their method achieves better sensitivity; however, our method achieves 
slightly better specificity. In addition, Akkus et al. [102] do not consider the global information of 
the tumor, since their dataset uses only 3 slices of the MRI sequence of each patient as input, not 
the whole volume of the tumor.  
Our analysis of ATRX-status prediction shows that tumor information-measure of 
correlation imaging feature and histogram mean tumor volume are the most frequently selected 
features. Higher values of information-measure of correlation associate significantly with WT 
ATRX status. This is in agreement with an ATRX mutation prediction study by Li et al. [58] (Table 
3) in patients with a low-grade glioma, where the authors use MRI texture feature and the LASSO 
regression model. In their model, information-measure of correlation is one of the features that is 
used to predict ATRX mutation.  In addition, our analysis shows that the tumor information-
measure of correlation is one of the most frequent features in the TERT model as well. This can be 
explained by the fact that ATRX and TERT mutations are mutually exclusive. 
The TERT prediction analysis shows that tumor information-measure of correlation and 
upper-left edema bounding box are the most frequently selected features. Higher values of these 
two features are significantly associated with mutated TERT status. The information-measure of 
correlation assesses the correlation/dependency between two gray-levels using mutual information 
content. Higher values of information-measure of correlation are associated with mutated TERT. 
In addition, our analysis suggests that the higher values of Inverse difference moment of HE 
associates significantly with WT TERT and offers HR = 0.612 per standard deviation with a 
likelihood ratio test, p-value = 0.03. Inverse difference moment measures local homogeneity. High 
values of inverse difference moment of an HE tumor predict the less aggressive WT TERT.  
Overall, our analysis shows that the necrosis location and the necrosis volume-related 
features are very important (most frequently selected features) in MGMT, IDH, and 1p/19q 
codeletion prediction. Edema volume-related features are very important in IDH and TERT 
prediction models. Fractal features have a significant effect on MGMT, IDH, 1p/19q codeletion, 
and ATRX prediction models. Further analysis of the most frequent features in each prediction 
model indicates that the effect of thresholding the value of the standardized feature around the 
43 
 
median can stratify the 108 cases significantly (log-rank test, p-value < 0.05) into two survival 
groups (Figure 8a-c). The features and the median survival of each group are: 
• the size ratio between the enhanced tumor and necrosis stratifies the 108 cases into two groups 
with a median survival of 87.4 months vs 30.7 months,  
• the correlation of the tumor volume stratifies the 108 cases into two groups with a median 
survival of 114 months vs 46 months, 
• and the vertical orientation of edema major axis stratifies the 108 cases into two groups with a 
median survival of 114 vs 44 months. 
In summary, this study presents molecular prediction model designs from traditional MRI 
data based on the 2016 update of the WHO classification of LGG of the CNS. Our prediction 
model performance shows promise when compared to other methods and models in the literature. 
An association among computed MR imaging features and the molecular mutations LGG was 
established. The methods discussed in our study are important steps towards non-invasive imaging 
classification of diffuse LGG based on molecular mutations prior to invasive tissue sampling. In 
this work for the first time in the literature, we hypothesize that fractal and multi-resolution fractal 
features have an association with molecular prediction. The feature selection using RFS and the 
subsequent prediction results in Table 1 confirm our hypothesis by showing the efficacy of these 
fractal features in glioma prediction. Therefore, this work may be considered as a validation of 
previously hypothesized fractal biomarkers and, hence, may have the potential for generalizability 




Table 3. Comparison between our proposed molecular mutations models and state-of-the 
art glioma grading models. 
Our Proposed Prediction Models 
108 LGG (75% training, 25 testing) 
Other Models 
Models 
Test Performance (using 
testing sets) 
AUC, Sens., Spec. 













Kanas et al.[59] (86 
GBM patients) 
 
Acc, Sens., Spec. 
0.736, 0.85, 0.66 
Han et al. [99] (159 
LGG; 70% training, 
15% validation, and 
15% testing) 
AUC, Accuracy, Prec., Recall 
Testing: 0.61, 0.62, 0.67, 0.67 
















Accuracy, AUC, Sens., Spec. 
Training: 0.80, 0.86, 0.83, 0.74 













Akkus et al.[102] 
(159 LGG (252 
slices), validation (68 
slices), and testing 
(90 slices)). 
Accuracy Sens., spec. 












Li et al.[58] (95 
LGG, 63 training, 32 
validation, and 91 
external validation 
Accuracy, AUC, Sens. Spec. 
Validation: 0.938, 
0.925,0.83.3,1.00 







GLIOMA GRADING AND PREDICTION USING JOINT MODELING OF RNA 
SEQUENCING AND RADIOMICS IN A NEGATIVE BINOMIAL DISTRIBUTION 
 
4.1 CHAPTER OVERVIEW 
 
RNA sequencing (RNAseq) is a recent technology that profiles gene expression by 
measuring the relative frequency of the RNAseq reads. Contemporary literature lacks appropriate 
modeling for RNAseq distribution where the model is adaptive and also preserves the nature of 
RNAseq read counts data for glioma grading and prediction. Negative Binomial (NB) distribution 
may be useful to model RNAseq read counts data that addresses these shortcomings. In addition 
to RNAseq read counts data, radiomics has long played a pivotal role in current radiology practice 
such as disease diagnosis, monitoring, and treatment planning.  
In this study, we propose an RNA-radiomics (henceforth, radiogenomics) -NB model for 
glioma grading and prediction. Our radiogenomics-NB model is developed based on differentially 
expressed RNAseq and selected radiomics/volumetric features which characterize the tumor 
volume and its sub-regions. The NB distribution is fitted to RNAseq counts data, and a log-linear 
regression model is assumed to link between the estimated NB mean and radiomics. Three 
radiogenomics-NB molecular mutation models (e.g., IDH mutation, 1p/19q codeletion, and ATRX 
mutation) are investigated. Additionally, we explore the gender-specific effect on the 
radiogenomics-NB models.  
Finally, we compare the performance of the three mutation prediction radiogenomics-NB 
models with different well-known methods in the literature: Negative Binomial Linear 
Discriminant Analysis (NBLDA), differentially expressed RNAseq with Random Forest (RF-
genomics), radiomics and differentially expressed RNAseq with Random Forest (RF-
radiogenomics), and voom-based count transformation combined with the nearest shrinkage 
classifier (VoomNSC). Our analysis shows that the proposed radiogenomics-NB model 
significantly outperforms (ANOVA test, p-value < 0.05) for prediction of IDH and ATRX 
mutations and offers similar performance for prediction of 1p/19q codeletion, when compared to 




4.2 PREDICTION USING NEGATIVE BINOMIAL REGRESSION MODEL 
 
In this study, we propose a radiogenomics-NB method for glioma molecular grading and 
prediction. Figure 9 illustrates an overall flow diagram of the proposed radiogenomics model. In 
Figure 9a, we fit NB distribution to RNAseq read counts data of the training dataset and estimate 
the model mean and dispersion parameter. Then, we use the estimated mean along with the 
predictor radiomics vector in a log-linear regression model to estimate the model regression 
coefficients. The dispersion parameter is estimated using the weighted likelihood empirical Bayes 
[115]. In Figure 9b, the estimated parameters of regression coefficients and the dispersion 
parameters along with the sample radiomics and its RNAseq read counts are utilized to predict the 
class label of a future test sample. A complete mathematical derivation of the radiogenomics-NB 








Figure 9. Overall Flow diagram of the proposed radiogenomics-NB prediction model.a) 
radiogenomics-NB model utilizing the training data. b) class prediction of a test sample using the 
developed radiogenomics-NB model.  
 
 
4.2.1 Prediction using Negative Binomial regression model 
 
To fuse radiomics with RNAseq read counts data in an NB model, the following 
parametrization is defined: 
Let 𝐶𝐶  be the total number of classes, and 𝐼𝐼𝑐𝑐 ∈  (1, . . . ,𝑛𝑛𝑐𝑐) the indices of samples in class c 
for 𝑐𝑐 =  1, . . . ,𝐶𝐶. The examples of different classes include:  
o IDH mutated vs wildtype IDH (𝐶𝐶 = 2),   
o 1p/19q codeletion: codeletion vs non-codeletion (in this case 𝐶𝐶 = 2),   
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o Mutated ATRX vs wildtype (in this case 𝐶𝐶 = 2).  
let 𝑌𝑌𝑖𝑖  = (𝑦𝑦𝑖𝑖1,𝑦𝑦𝑖𝑖2, . . . ,  𝑦𝑦𝑖𝑖𝑖𝑖) be the RNAseq read counts training sample in the class label c  
and 𝐺𝐺 is the total number of RNAseq. The purpose of this study is to predict the class label 𝑐𝑐 of a 
future observation 𝑌𝑌𝑡𝑡 using training samples associated with known class labels: 𝑝𝑝( 𝑐𝑐|𝑌𝑌𝑡𝑡) ∝
𝑝𝑝(𝑌𝑌𝑡𝑡|𝑐𝑐)𝑝𝑝𝑐𝑐, where 𝑝𝑝𝑐𝑐 is the probability of class c. Using Bayes’ rule, we have, 
 
𝑝𝑝( 𝑐𝑐|𝑌𝑌𝑖𝑖) ∝ 𝑝𝑝(𝑌𝑌𝑖𝑖|𝑐𝑐)𝑝𝑝c;      (2) 
 
where 𝑝𝑝(𝑌𝑌𝑖𝑖| 𝑐𝑐) is the pdf of the sample 𝑌𝑌𝑖𝑖 in class c, and 𝑝𝑝c is the prior probability that one sample 
comes from class c. The pdf of class-specific c of RNAseq read counts of sample 𝑌𝑌𝑖𝑖 and gene 𝑔𝑔 is 
 







)𝜙𝜙𝑔𝑔−1 .  (3) 
 
In this parameterization, 𝑌𝑌𝑖𝑖𝑖𝑖 represents a count response of RNAseq, where 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 represents 
the mean, 𝜙𝜙𝑖𝑖 represents the dispersion parameter, 𝐸𝐸(𝑌𝑌𝑖𝑖𝑖𝑖) = 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐, and 𝑉𝑉𝑉𝑉𝑉𝑉(𝑌𝑌𝑖𝑖𝑖𝑖)  =  𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 + 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐𝜙𝜙𝑖𝑖2. 
Note we assume that all RNAseq are independent of each other, so we have, 
 
𝑝𝑝(𝑌𝑌𝑖𝑖|𝑍𝑍 = 𝑐𝑐)  =  ∏ 𝑃𝑃(𝑌𝑌𝑖𝑖𝑖𝑖 = 𝑦𝑦𝑖𝑖𝑖𝑖)𝑖𝑖𝑖𝑖=1 .    (4) 
 
Evaluating equation 2 requires an estimation of 𝑝𝑝(𝑌𝑌𝑖𝑖|𝑐𝑐) and 𝑝𝑝c. The model in equation 3 
states that 𝑌𝑌𝑖𝑖𝑖𝑖~𝑁𝑁𝑁𝑁(𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐,𝜙𝜙𝑖𝑖). We first estimate 𝜙𝜙1,𝜙𝜙2, . . . ,𝜙𝜙𝑖𝑖  and 𝜇𝜇𝑖𝑖1𝑐𝑐 , 𝜇𝜇𝑖𝑖2𝑐𝑐 , . . . , 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 of all the 
training samples 𝑛𝑛𝑐𝑐, and all RNAseq 𝐺𝐺. The mean is estimated as 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 = 𝑠𝑠𝑖𝑖𝑐𝑐𝜆𝜆𝑖𝑖𝑐𝑐, where 𝑠𝑠𝑖𝑖𝑐𝑐 is the 
size factor [139, 140] which is used to scale RNAseq counts for the 𝑖𝑖𝑖𝑖ℎ sample (in class c), 𝜆𝜆𝑖𝑖𝑐𝑐 is 
the total number of reads of RNAseq 𝑔𝑔 across all samples in class c. Regarding the prior 𝑝𝑝c, we 
assume all classes are equally likely 𝑝𝑝𝑐𝑐 = 1 𝐶𝐶⁄ . Note that 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐,  𝑠𝑠𝑖𝑖𝑐𝑐 ,𝑉𝑉𝑛𝑛𝑎𝑎 𝜆𝜆𝑖𝑖𝑐𝑐 are estimated for each 
class 𝑐𝑐.  
Next, plugging these estimates into equation 3 and using the assumption of independent 
RNAseq, equation 2 yields,  
 




The log-likelihood 𝑙𝑙𝑙𝑙𝑔𝑔(𝑝𝑝(𝑌𝑌𝑖𝑖|𝑐𝑐)) is written as, 
 








)𝜙𝜙𝑔𝑔−1).    (6) 
 
Equation 6 can be written as, 
 
𝑙𝑙𝑙𝑙𝑔𝑔(𝑝𝑝(𝑌𝑌𝑖𝑖|𝑐𝑐)) =  ∑ 𝑙𝑙𝑙𝑙𝑔𝑔(
𝜙𝜙𝑔𝑔𝜇𝜇𝑖𝑖𝑔𝑔𝑖𝑖
1+𝜙𝜙𝑔𝑔𝜇𝜇𝑖𝑖𝑔𝑔𝑖𝑖
)𝑦𝑦𝑖𝑖𝑔𝑔𝑖𝑖𝑖𝑖=1  + ∑ 𝑙𝑙𝑙𝑙𝑔𝑔(
1
1+𝜙𝜙𝑔𝑔𝜇𝜇𝑖𝑖𝑔𝑔𝑖𝑖
)𝜙𝜙𝑔𝑔−1𝑖𝑖𝑖𝑖=1  + ∑ 𝑙𝑙𝑙𝑙𝑔𝑔(
Γ(𝜙𝜙𝑔𝑔−1+𝑦𝑦𝑖𝑖𝑔𝑔)
Γ(𝜙𝜙𝑔𝑔−1)𝑦𝑦𝑖𝑖𝑔𝑔!
)𝑖𝑖𝑖𝑖=1 .     (7) 
 
Rewriting equation 7 yields,  
 




𝜙𝜙𝑖𝑖𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐)   + ∑ 𝑙𝑙𝑙𝑙𝑔𝑔(
𝛤𝛤(𝜙𝜙𝑔𝑔−1+𝑦𝑦𝑖𝑖𝑔𝑔)
𝛤𝛤(𝜙𝜙𝑔𝑔−1)𝑦𝑦𝑖𝑖𝑔𝑔!
)𝑖𝑖𝑖𝑖=1 .    (8) 
 
The proposed NB model of genomics relates to the radiomics (imaging features) 𝑿𝑿 through 
the mean parameters 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 (estimated mean of an 𝑖𝑖𝑖𝑖ℎ sample and RNAseq g in class c). We assume 
a log-linear regression model for estimated the mean 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 in terms of the radiomics (imaging 
features) as follows: 
 
𝑙𝑙𝑙𝑙𝑔𝑔(𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐) =  𝑋𝑋𝑖𝑖𝛽𝛽𝑖𝑖𝑐𝑐;     (9.a) 
𝑙𝑙𝑙𝑙𝑔𝑔(𝑠𝑠𝑖𝑖𝑐𝑐𝜆𝜆𝑖𝑖𝑐𝑐) =  𝑋𝑋𝑖𝑖𝛽𝛽𝑖𝑖𝑐𝑐 ;     (9.b) 
 
where 𝑋𝑋𝑖𝑖 is a 𝑝𝑝-dimensional of radiomics,  𝛽𝛽𝑖𝑖𝑐𝑐 is a 𝑝𝑝-dimensional vector of unknown regression 
coefficients (translate the relationship between 𝑋𝑋 and 𝑌𝑌 through 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 ). The estimation of 𝛽𝛽𝑖𝑖𝑐𝑐 
depends on class 𝑐𝑐 and gene 𝑔𝑔 of the 𝑖𝑖𝑖𝑖ℎ sample. Hence, if there are two classes, we will need to 
estimate 𝛽𝛽𝑖𝑖1and 𝛽𝛽𝑖𝑖2  (one from each class). Plugging equation 9.a into equation 8, yields, 
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𝑙𝑙𝑙𝑙𝑔𝑔(𝑝𝑝(𝑌𝑌𝑖𝑖|𝑐𝑐))  =  ∑ 𝑦𝑦𝑖𝑖𝑖𝑖𝑙𝑙𝑙𝑙𝑔𝑔(𝜙𝜙𝑖𝑖𝑒𝑒𝑥𝑥𝑝𝑝(𝑋𝑋𝑖𝑖𝛽𝛽𝑖𝑖𝑐𝑐 + 𝜀𝜀))𝑖𝑖𝑖𝑖=1  −  ∑ 𝑦𝑦𝑖𝑖𝑖𝑖𝑙𝑙𝑙𝑙𝑔𝑔(1 + 𝜙𝜙𝑖𝑖𝑒𝑒𝑥𝑥𝑝𝑝(𝑋𝑋𝑖𝑖𝛽𝛽𝑖𝑖𝑐𝑐 +𝑖𝑖𝑖𝑖=1
𝜀𝜀))  − ∑ 1
𝜙𝜙𝑔𝑔
𝑙𝑙𝑙𝑙𝑔𝑔(1 + 𝜙𝜙𝑖𝑖𝑒𝑒𝑥𝑥𝑝𝑝(𝑋𝑋𝑖𝑖𝛽𝛽𝑖𝑖𝑐𝑐 + 𝜀𝜀))𝑖𝑖𝑖𝑖=1   + ∑ 𝑙𝑙𝑙𝑙𝑔𝑔(
𝛤𝛤(𝜙𝜙𝑔𝑔−1+𝑦𝑦𝑖𝑖𝑔𝑔)
𝛤𝛤(𝜙𝜙𝑔𝑔−1)𝑦𝑦𝑖𝑖𝑔𝑔!
)𝑖𝑖𝑖𝑖=1 .   (10) 
 
Using the estimated ?̂?𝛽𝑖𝑖𝑐𝑐, and 𝜙𝜙�𝑖𝑖 from the training data, if we classify a test observation 𝑌𝑌𝑡𝑡 
as follows, 
 




𝑙𝑙𝑙𝑙𝑔𝑔(𝑝𝑝(𝑐𝑐|𝑌𝑌𝑡𝑡))  =  ∑ 𝑦𝑦𝑡𝑡𝑖𝑖𝑙𝑙𝑙𝑙𝑔𝑔(𝜙𝜙�𝑖𝑖𝑒𝑒𝑥𝑥𝑝𝑝(𝑋𝑋𝑡𝑡?̂?𝛽𝑖𝑖𝑐𝑐))𝑖𝑖𝑖𝑖=1  −  ∑ 𝑦𝑦𝑡𝑡𝑖𝑖𝑙𝑙𝑙𝑙𝑔𝑔(1 + 𝜙𝜙�𝑖𝑖𝑒𝑒𝑥𝑥𝑝𝑝(𝑋𝑋𝑡𝑡?̂?𝛽𝑖𝑖𝑐𝑐))𝑖𝑖𝑖𝑖=1  −
∑ 1
𝜙𝜙𝑔𝑔
𝑙𝑙𝑙𝑙𝑔𝑔(1 + 𝜙𝜙�𝑖𝑖𝑒𝑒𝑥𝑥𝑝𝑝(𝑋𝑋𝑡𝑡?̂?𝛽𝑖𝑖𝑐𝑐))𝑖𝑖𝑖𝑖=1   + ∑ 𝑙𝑙𝑙𝑙𝑔𝑔(
𝛤𝛤(𝜙𝜙�𝑔𝑔−1+𝑦𝑦𝑡𝑡𝑔𝑔)
𝛤𝛤(𝜙𝜙�𝑔𝑔−1)𝑦𝑦𝑡𝑡𝑔𝑔!
)𝑖𝑖𝑖𝑖=1  +  𝑙𝑙𝑙𝑙𝑔𝑔(𝑝𝑝𝑐𝑐). (12) 
 
4.2.2 ESTIMATING DISPERSION PARAMETER 𝝓𝝓𝒈𝒈 USING WEIGHTED 
LIKELIHOOD EMPIRICAL BAYES. 
 
Various methods for estimating the dispersion parameter 𝜙𝜙𝑖𝑖 are proposed in the literature. 
EdgeR applies a weighted conditional log-likelihood method to estimate dispersion parameter 
[115]. The weighted conditional log-likelihood (WL) for 𝜙𝜙𝑖𝑖is defined as a weighted combination 
of the individual (per-gene) likelihood 𝑙𝑙𝑖𝑖(𝜙𝜙𝑖𝑖) and common 𝑙𝑙𝐶𝐶(𝜙𝜙𝑖𝑖) likelihood: 
 
𝑊𝑊𝑊𝑊(𝜙𝜙�𝑖𝑖)  =  𝑙𝑙𝑖𝑖(𝜙𝜙𝑖𝑖)   +  𝛼𝛼𝑙𝑙𝐶𝐶(𝜙𝜙𝑖𝑖);     (13) 
 
where 𝛼𝛼 is the weight of 𝑙𝑙𝐶𝐶(𝜙𝜙𝑖𝑖).  
 
In EdgeR, 𝜙𝜙�𝑖𝑖 is assumed to be normally distributed with means 𝜙𝜙𝑖𝑖 and known variance 
𝜏𝜏2, and has the following hierarchical model: 
 
𝜙𝜙�𝑖𝑖|𝜙𝜙𝑖𝑖~𝑁𝑁(𝜙𝜙𝑖𝑖, 𝜏𝜏2),𝑉𝑉𝑛𝑛𝑎𝑎 𝜙𝜙𝑖𝑖~𝑁𝑁(𝜙𝜙0, 𝜏𝜏02).    (14) 
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Under this hierarchical normal model, the maximum weighted conditional log-likelihood 




�𝑔𝑔 𝜏𝜏2⁄  +𝛼𝛼∑ 𝜙𝜙�𝑖𝑖 𝜏𝜏𝑖𝑖
2�𝐺𝐺𝑖𝑖=1  
1 𝜏𝜏2⁄  +𝛼𝛼∑ 1 𝜏𝜏𝑖𝑖
2⁄𝐺𝐺𝑖𝑖=1













.     (17) 
 
4.2.3 COMPUTATION OF THE MEAN OF RNASEQ 𝝁𝝁𝒊𝒊𝒈𝒈𝒄𝒄 
 
The size factor 𝑠𝑠𝑖𝑖𝑐𝑐 of sample 𝑖𝑖 and class c is the total number of RNAseq read counts of 
that sample divided by the total number of all RNAseq read counts across all training samples (in 
class 𝑐𝑐).  The size factor estimation is vital to account for the different sequencing depth (library 
size) that may be used to sequence different samples.  
The mean 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 of sample 𝑖𝑖 and RNAseq 𝑔𝑔 in class c is then estimated as 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐 = 𝑠𝑠𝑖𝑖𝑐𝑐𝜆𝜆𝑖𝑖𝑐𝑐, 
where 𝜆𝜆𝑖𝑖𝑐𝑐 is the total number of reads per RNAseq in class c. Using the estimated value of 𝜇𝜇𝑖𝑖𝑖𝑖𝑐𝑐, 
the values of 𝛽𝛽𝑖𝑖𝑐𝑐 are computed using equation 9.a. The algorithm in Figure 10 illustrates the steps 
of estimating the different parameters in the radiogenomics Negative Binomial classification 













The dataset in this study consists of 108 pre-operative LGG patients that are described in 
[123, 124, 141]. Four sequences of the MRI are provided with the dataset: pre-contrast T1-
weighted (T1), post-contrast T1-weighted (T1Gd), T2-weighted (T2), and T2 Fluid Attenuated 
Inversion Recovery (FLAIR). These scans are skull-stripped, re-sampled to 1 mm3 resolution, and 
co-registered to the T1 template. The dataset provides the segmented sub-regions of the LGG: 
Gadolinium enhanced tumor (ET), the peritumoral edema (ED), and the necrosis along with non-
contrast enhancing tumor (NCR/NET). RNAseq read counts data (with a total number of 56830 
RNAseq), molecular alterations (IDH mutation, 1p/19q codeletion, and ATRX), grade (II and III), 
and the clinical dataset is downloaded from the Genomic Data Commons Data Portal 
(https://portal.gdc.cancer.gov/). The clinical dataset is de-identified by the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA). The distribution of the data is as follows: (i) 
IDH mutation: 85 Mutant and 23 wildtype (WT), (ii) 1p/19q codeletion: 27 codeletion and 81 non-
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codeletion, and (iii) ATRX status: 43 Mutant and 65 WT. The range of the patients’ age at diagnosis 
is 20 – 75 years, and the median age is 46.5 years. 
 
4.3.2 DATA PREPARATION  
 
In this study of glioma molecular grading and prediction, for the dataset of 108 LGG cases, 
we obtain two types of features (i.e. radiomics and RNAseq read counts data) and 3 molecular 
mutation types. The three molecular types are (i) IDH mutation: 85 Mutant and 23 wildtype (WT), 
(ii) 1p/19q codeletion: 27 codeletion and 81 non-codeletion, and (iii) ATRX mutation: 43 Mutant 
and 65 WT. 
We first filter RNAseq read counts to remove RNAseq with a very low value of read counts 
before performing any statistical analysis. RNAseq with very low read counts holds very little 
information because an RNAseq of biological importance needs to be expressed at some minimal 
level. We utilize a quantile filter [142] with a quantile threshold of 0.25. This step returns each 
RNAseq that has a mean across all samples higher than the defined quantile threshold of 0.25. 
Then, we reduce the number of RNAseq that are used in the radiogenomics-NB models by utilizing 
EdgeR [116] to extract the differentially expressed RNAseq (DERs). DERs reflect the significance 
of a gene in a certain biological condition. In this study, we select the top 10, 20, 30, 50, 100, and 
150 DERs. 
Furthermore, we use eight volumetric radiomics features as illustrated in Table 4. ANOVA 
analysis for radiomics in Table 4 shows that feature numbers 1, 3, 4, 7, and 8 are significantly 
associated (ANOVA test, p-value < 0.05) with IDH mutations. Our analysis also indicates that 
feature number 2 is marginally associated (ANOVA test, p-value = 0.07) with 1p/19q codeletion. 
Furthermore, our analysis indicates that feature numbers 3, 4, 6, 7, and 8 are significantly 
associated (ANOVA test, p-value < 0.05) with ATRX mutations. Few other studies suggest that 
these volumetric imaging features and their ratios are associated with and predictive of several 




Table 4. Radiomics features description and their ANOVA p-value association with IDH 











the size of the enhanced tumor to the 
necrosis size 
0.0033 0. 393 0.178 
2 
the size of the enhanced tumor to the size 
of enhanced tumor and necrosis 
0.8630 0.070 0.239 
3 
the size of the enhanced tumor to the 
edema size 
<0.005 0.600 0.002 
4 
the size of the enhanced tumor to the 
whole tumor size, 
<0.005 0.707 0.027 
5 the size of the edema to the necrosis size, 0.188 0.996 0.114 
6 
the size of the edema to the size of 
enhanced tumor and necrosis 
0.138 0.789 0.0237 
7 
the size of the edema to the whole tumor 
size 
<0.005 0.131 <0.005 
8 
and the size of the necrosis to the whole 
tumor size 
<0.005 0.221 <0.005 
 
 
The 108 LGG cases are randomly split into 80% training and 20% testing sets, and a 
balanced distribution of the target molecular alteration is ensured in the training and testing sets in 
each molecular classifier. The trained model classifier is developed using the training set. Model 
performance prediction is estimated and reported using the testing sets in terms of accuracy, 
balanced accuracy, F1 score, sensitivity, specificity, negative predictive value, and positive 
predictive value. The training set is utilized to build our radiogenomics-NB classifier as shown in 
steps 1-4 in Figure 10. The testing set is used to estimate the performance of the classifier as shown 
in steps a and b in Figure 10. Authors in [119, 147-149] repeat training and testing analysis for a 
specific number of times to ensure the robustness of the model performance. Consequently, in this 
work, we repeat the whole procedure 100 times independently for the 3 molecular alterations and 




4.4 RADIOGENOMICS-NB MODELS USING DIFFERENT NUMBERS OF 
DIFFERENTIALLY EXPRESSED RNAS 
 
In this section, we investigate the importance of using different numbers of DERs on the 
performance of the radiogenomics-NB model. LGG radiogenomics-NB mutation prediction 
models are developed based on the top 10, 20, 30, 50, 100, and 150 DERs.  
The performance of the radiogenomics-NB IDH model using the top 10 DERs achieves 
slightly high performance. However, such improvement is not statistically significant (ANOVA 
test, p-value > 0.05) when compared to the performance of the IDH models with the other number 
of DERs (Figure 11.a) except for NPV performance when using the top 20 DERs. Using the top 
20 DERs in the IDH model achieves significantly (ANOVA test, p-value < 0.05) worse NPV when 
compared to the NPV achieved using the top 10 DERs. Radiogenomics-NB IDH model with the 
top 10 DERs (red line in Figure 11.a) achieves an overall accuracy (Acc) of 0.92±0.06, sensitivity 
(Sens) of 0.94±0.07, specificity (Spec) of 0.83±0.18, positive predictive value (PPV) of 0.96±0.04, 
negative predictive value (NPV) of 0.82±0.17, F1 score of 0.95±0.04, and balanced accuracy (B. 
Acc) of 0.88±0.09, respectively.  
Radiogenomics-NB codeletion models significantly achieve similar performance 
(ANOVA test, p-value > 0.05) using the top 10, 20, 30, and 50 DERs as shown in Figure 11.b. 
Furthermore, using the top 100 and 150 DERs in the codeletion model achieves worse performance 
(ANOVA test, p-value > 0.05) when compared to the performance of using the top 10 DERs. Using 
the top 10 DERs, the radiogenomics-NB codeletion model achieves an accuracy of 0.93±0.06, a 
balanced accuracy of 0.90±0.10, F1 score of 0.86±0.14, a sensitivity of 0.84±0.19, a specificity of 
0.96±0.04, an NPV of 0.95±0.06, and a PPV of 0.90±0.12, respectively.  
The radiogenomics-NB ATRX model achieves similar performance (ANOVA test, p-value 
> 0.05) using the top 10, 20, and 30 DERs, even though the performance when using the top 10 
DERs is slightly better as illustrated in Figure 11.c. Using the top 10 DERs, the ATRX model 
achieves an accuracy of 0.85±0.07, a balanced accuracy of 0.85±0.07, an F1 score of 0.82±0.08, a 
sensitivity of 0.86±0.13, a specificity of 0.85±0.09, an NPV of 0.91±0.08, and a PPV of 0.80±0.10, 
respectively. Table 5 illustrates the confusion matrix of the test performance of the radiogenomics-







Figure 11. Performance of the proposed radiogenomics-NB model using a different 
number of DERs. a) Radiogenomics-NB IDH, b) Radiogenomics-NB Codeletion, and c) 
Radiogenomics-NB ATRX models. The average performance (of the Acc, B. Acc, F1, NPV, PPV, 
Sens, and Spec) is computed across 100 testing sets/splits. Y-axis represents the average 
performance of the different statistics on the X-axis. Different colors represent the radiogenomics-
NB model with different numbers of DERs. The error bar represents one standard deviation. 
Asterisk “*” represents a statically significant difference between the performance achieved when 
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Table 5. Confusion matrix of test performance over 100 repetitions of radiogenomics-NB 
IDH, Codeletion, and ATRX models using the top 10 DERs. 





 References  References  References 
Predictions Mutant WT Predictions Codel. Non-codel Predictions Mutant WT 
Mutant 1503 69 Codel. 421 53 Mutant 690 184 
WT 97 331 Non-codel 79 1447 WT 110 1016 
 
 
4.5 COMPARATIVE ANALYSIS 
 
Figure 12 illustrates a graphical performance comparison between our radiogenomics-NB 
model with that of four different classifiers in the literature: NBLDA [119], VoomNSC [65, 66], 
RF-genomics where we first log-transformed [116] the RNAseq into a normal distribution, and 
RF-radiogenomics. Note that the number of DERs that we apply to develop these classifiers is 10 
DERs. Moreover, when developing these classifiers, the 108 LGG cases are randomly split into 
80% training and 20% testing sets, and balanced distribution is ensured when developing the 
different classifiers. The trained model classifier is developed using the training set, and 10-fold 
cross-validation is performed to identify the tuning parameters in the different classifiers. Model 
performance prediction is estimated and reported using the testing sets. Additionally, to ensure the 
robustness of the different classifiers’ performance, we repeat the whole procedure 100 times 
independently and every training/testing set is utilized to develop and estimate the performance of 
each classifier.   
The NBLDA [119] classifier is developed by fitting NB to the top 10 DERs; then the mean 
and dispersion parameter are estimated from these DERs. In RF-genomics, the top 10 DERs of the 
training sets are first log-transformed into normal distribution and then fed into RF to build the 
RF-genomics classifier. In RF-radiogenomics, radiomics (eight volumetric features described 
previously in Table 4) are utilized with the log-transformed DERs and then fed into RF to build 
the RF-radiogenomics classifier. VoomNSC [65, 121] is developed by first applying the voom-




Comparing the performance of our radiogenomics-NB IDH model with that of NBLDA, 
RF-genomics, and VoomNSC, the radiogenomics-NB IDH significantly outperforms (ANOVA 
test, p-value < 0.05) these methods as shown in Figure 12.a and Table 6. Additionally, our 
radiogenomics-NB IDH model significantly outperforms (ANOVA test, p-value  < 0.05)  the F1 
score, balanced accuracy, and PPV performance of the RF-radiogenomics method whereas it 
achieves a similar (ANOVA test, p-value > 0.05) accuracy, sensitivity, and specificity. Our 
radiogenomics-NB IDH model archives an accuracy of 0.92±0.06, a sensitivity of 0.94±0.07, a 
specificity of 0.93±0.18, an F1 score of 0.95±0.04, and a balanced accuracy of 0.88±0.09, 
respectively. The RF-radiogenomics-IDH model achieves an accuracy of 0.88±0.17, a sensitivity 
of 0.93±0.07, a specificity of 0.78±0.16, an F1 score of 0.92±0.06, and a balanced accuracy of 
0.85±0.08, respectively. 
Our radiogenomics-NB codeletion model (Figure 12.b and Table 7) performance is similar 
to NBLDA, RF-genomics, VoomNSC, and RF-radiogenomics models, except for the specificity 
and NPV performance when using RF-genomics and VoomNSC. The specificity and NPV of our 
model are significantly higher than those achieved by RF-genomics and VoomNSC. Our 
radiogenomics-NB codeletion model achieves an accuracy of 0.93±0.06, a sensitivity of 
0.84±0.20, a specificity of 0.96±0.5, an F1 score of 0.86±0.14, and a balanced accuracy of 
0.90±0.10, respectively. 
The performance of our radiogenomics-NB ATRX model as shown in Figure 12.c and Table 
8 outperforms both NBLDA and VoomNSC significantly (ANOVA test, p-value < 0.05). 
However, comparing our ATRX model to RF-genomics, our model achieves significantly better 
balanced-accuracy, F1 score, NPV, and sensitivity. Additionally, comparing our ATRX model to 
RF-radiogenomics, our model achieves significantly (ANOVA test, p-value < 0.05) better 
sensitivity but achieves similar accuracy, balanced-accuracy, F1 score, and sensitivity. Our 
radiogenomics-NB ATRX model achieves an accuracy of 0.85±0.07, a sensitivity of 0.86±0.13, a 
specificity of 0.85±0.09, an F1 score of 0.82±0.08, and a balanced accuracy of 0.85±0.07, 
respectively. The RF-radiogenomics ATRX model achieves an accuracy of 0.84±0.08, a sensitivity 








Figure 12. Comparison of performance between our radiogenomics-NB model and 
different classifiers. The comparison is performed using the a) IDH mutation, b) 1p/19q codeletion, 
and c) ATRX mutations dataset. The average performance (of the Acc, B. Acc, F1, NPV, PPV, Sens, 
and Spec) is computed across 100 test sets. The error bar represents one standard deviation. RNAseq 
that are used in developing all classifiers represent the top 10 DERs in the training sets between 
mutated and WT IDH group, codeleted and non-codeleted groups, and mutated and WT ATRX 
mutation, respectively. Y-axis represents the average performance of the different statistics on the 
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Table 6. Probability of significant difference using ANOVA test between the differentially 
expressed radiogenomics-NB model and different classifiers using IDH dataset. A statistically 
significant difference exists if p-value < 0.05. Values in bold show a significant improvement of our 
radiogenomics-NB IDH over the compared one. 





0.000 0.010 0 0 0.000 0.000 0 
radiogenomics-NB 
VS VoomNSC 
0.000 0.075 0 0 0.000 0.000 0 
radiogenomics-NB 
VS RF 




0.069 0.432 0.061 0 0.084 0.001 0.01 
 
 
Table 7. Probability of significant difference using ANOVA test between the differentially 
expressed radiogenomics-NB model and different models using 1p/19q codeletion dataset. A 
statistically significant difference exists if p-value < 0.05. Values in bold show a significant 
improvement of our radiogenomics-NB codeletion over the compared one. 





0.232 0.186 0.756 0.514 0.253 0.123 0.181 
radiogenomics-NB 
VS VoomNSC 
0.072 0.228 0.001 0.057 0.042 0.742 0.317 
radiogenomics-NB 
VS RF 









Table 8. Probability of significant difference using ANOVA test between the differentially 
expressed radiogenomics-NB model and different models using ATRX dataset. A statistically 
significant difference exists if p-value < 0.05. Values in bold show a significant improvement of our 
radiogenomics-NB ATRX over the compared one. 





0.000 0.269 0.000 0.000 0.677 0.004 0.001 
radiogenomics-NB 
VS VoomNSC 
0.003 0.741 0.001 0.002 0.432 0.021 0.012 
radiogenomics-NB 
VS RF 




0.183 0.003 0.215 0.561 0.003 0.052 0.053 
 
 
4.6 GENDER-SPECIFIC EFFECT ANALYSIS OF RADIOGENOMICS-NB  
 
In our LGG dataset, IDH mutated patients, unlike IDH WT patients, have significantly 
longer survival (65.7 vs 19.9 months, log-rank test p-value = 0.004). The association between IDH 
status and overall survival remains significant after stratifying for gender (likelihood ratio test p-
value = 0.015). However, the association between 1p/19q codeletion and ATRX status and overall 
survival is not significant. Additionally, the chi-square test shows no significant association (p-
value > 0.05) between gender and IDH status, 1p/19q codeletion, and ATRX status. Table 9 shows 
patient IDH status, 1p/19q codeletion, and ATRX status distribution based on gender. 
To explore the gender-specific effect in the performance of the radiogenomics-NB, we 
build two radiogenomics-NB models based on gender; male-specific radiogenomics-NB and 
female-specific radiogenomics-NB. Our analysis indicates that female-specific models outperform 
significantly (ANOVA test, p-value < 0.05) male-specific models as illustrated in Figure 13. 
Female-specific models achieve an accuracy of 0.93±0.08 and a balanced accuracy of 0.92±0.11 
in the radiogenomics-NB IDH, an accuracy of 0.91±0.09 and a balanced accuracy of 0.84±0.17 in 
the radiogenomics-NB codeletion, and an accuracy of 0.80±0.11 and a balanced accuracy of 





Table 9. Gender-based distribution of IDH status, 1p/19q codeletion, and ATRX status in 
the LGG dataset. 
 IDH status 1p/19q codeletion ATRX status 
 Mutant WT Codeletion Non-Codeletion Mutant WT 
Female 43 14 14 43 24 33 





Figure 13. Gender-based radiogenomics-NB models performance of a) IDH mutations, b) 
1p/19q codeletion, and c) ATRX mutations which is computed across 100 testing sets. The error bar 
represents one standard deviations. The asterisk * illustrates a significant difference between two 
measurements. Y-axis represents the average performance of the different statistics on the X-axis. 












In this study, we propose a novel radiogenomics-NB model to fuse radiomics (imaging 
features) with RNAseq (genes) for glioma grading and prediction. NB distribution is appropriate 
for modeling RNAseq discrete read counts data and for preserving the count-based nature of this 
data. In the proposed radiogenomics-NB model, log-linear regression modeling is fitted to the 
estimated mean of the NB distribution and is linked with radiomics. We introduce this step to fuse 
the continuous radiomics data with the RNAseq count-based data without the need to transform 
the RNAseq data into a normal distribution.  
NB, unlike Poisson distribution, has two parameters; the mean (e.g., the expected value of 
the RNAseq read counts data) and dispersion (e.g., a parameter that helps in capturing the 
variability of the RNAseq read counts). If the dispersion of NB is zero, the model reduces to 
Poisson distribution. In Poisson distribution, the mean is equal to the variance, which makes it 
rather restrictive. However, variation is usually observed in the real data of RNAseq counts data 
that the Poisson distribution cannot handle properly. On the other hand, NB has an additional 
parameter called the “dispersion” that allows the NB distribution of RNAseq counts data to modify 
its variance without affecting the mean. Thus, NB serves as a practical approximation to model 
RNAseq count data with variability different from its mean. 
The mean of the proposed radiogenomics-NB model is estimated as the size factor 
multiplied by the total number of reads per RNAseq. Moreover, we utilize EdgeR to estimate the 
dispersion of the proposed radiogenomics-NB assuming RNAseq variability is assessed using the 
weighted conditional log-likelihood model. In the weighted conditional model, RNAseq counts 
data is assumed to have a distinct and individual dispersion for each RNAseq in addition to a 
common dispersion. Such an assumption can be more reliable when estimating the dispersion of 
real data of RNAseq counts data. 
The performance evaluation of the proposed work indicates that linking radiomics (i.e. 
tumor volumetric features) to RNAseq improves the performance of IDH and ATRX mutations 
prediction. The radiomics features utilized in the proposed radiogenomics-NB model that are 
described in Table 1 mainly depend on volumetric features. Our analysis shows that these features 
are associated with glioma mutations. This outcome supports previous studies that show the 
association between volumetric features and glioma mutations [143-146].  
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The efficacy of the proposed radiogenomics-NB model is further investigated using the top 
10, 20, 30, 50, 100, and 150 DERs, respectively as illustrated in Figure 12. Our analysis shows 
that the smaller the number of DERs (fewer than 30 DERs) utilized in radiogenomics-NB, the 
better the radiogenomics-NB model performance. Our analyses indicate that using fewer than 30 
DERs in our analysis offers the best performance (statically significant) in the radiogenomics-NB 
codeletion and ATRX prediction model. This suggests that using large numbers of DERs (more 
than 30) in the proposed radiogenomics-NB would over parametrize the dataset and create model 
fitting problems and thus degrade the performance.  
Comparing our radiogenomics-NB model to NBLDA, RF-genomics, FR-radiogenomics, 
and VoomNSC, our model significantly outperforms NBLDA, RF-genomics, and VoomNSC for 
prediction of IDH and ATRX mutations. Our radiogenomics-NB model offers similar performance 
as NBLDA, RF-genomics, RF-radiogenomics, and VoomNSC models for prediction of 1p/19q 
codeletion. Specifically, for prediction of IDH mutations, while the proposed radiogenomics-NB 
model achieves significantly better balanced-accuracy, F1 score, and PPV than RF-radiogenomics, 
our model achieves similar accuracy, sensitivity, and specificity. Such results indicate the power 
of fusing radiomics and genomics data to develop radiogenomics models for classification and 
prediction models. The findings in this work indicate that the radiomics volumetric features may 
be vital for the prediction of IDH and ATRX mutations along with the genomics.  
Different studies have revealed that gender is a significant factor in identifying cancer 
survival, prognosis, and treatment response [150-152]. Hence, improved glioma molecular 
mutation prediction may require the development of gender-specific models. In this study, we 
explore the gender-specific effect on the radiogenomics-NB models. Our analysis reveals that IDH 
mutated patients have significantly longer survival and remain significant after stratifying for 
gender, unlike 1p/19q codeletion and ATRX status. Moreover, our analysis indicates that no 
association is found between gender and the three mutations (IDH mutations, 1p/19q codeletion, 
and ATRX status) using the Chi-square test. This result is in agreement with the findings in [153-
155]. However, a gender-specific radiogenomics-NB model shows that female-specific 
radiogenomics-NB models significantly outperform the male-specific radiogenomics-NB models 
for prediction of IDH status, 1p/19q codeletion, and ATRX status, respectively. 
There are several limitations to this study. First, the radiogenomics-NB model is proposed 
to employ the count-based nature of the RNAseq dataset. We utilize both the sensitivity (the 
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probability of test positive when the test is positive) and the specificity (the probability of test 
negative when the test is negative) to assess the predictivity of the model. However, using the 
measurements of sensitivity and specificity may be not adequate when the normality of the data 
cannot be obtained [156]. Second, we assume that all RNAseq counts dataset are independent of 
each other in the derivation of the radiogenomics-NB model. This assumption may not be always 
realistic, and a gene interaction may affect a certain glioma outcome. 
In conclusion, we present a glioma mutations radiogenomics-NB prediction model that 
preserves the count nature of RNAseq counts data in the NB model and utilizes radiomics to 
develop a complete and a better characterization prediction model of patient data. Our analysis 
shows the superiority of utilizing both genomics and radiomics data when compared to only 
genomics models. Finally, this study shows the efficacy of volumetric radiomics features in the 






RADIOMICS-GUIDED PREDICTION OF OVERALL SURVIVAL IN 
GLIOBLASTOMA PATIENTS  
 
5.1 CHAPTER OVERVIEW 
 
Radiomics is defined as quantitative imaging features that are extracted from radiographic 
images (e.g., MRI). Radiomics have provided insights into personalized medicine and, thus, 
provided accurate survival prediction (i.e. risk stratification), tumor detection, subtype 
classification, and therapeutic response assessment of oncologic patients [157]. Additionally, 
different studies [30, 75, 88, 89, 158] study tumor heterogeneity using different types of imaging 
such as MRI. As a result, MRI is suggested as a potential non-invasive imaging biomarker for 
gliomas diagnostic, prognostic, and survival prediction. This chapter proposes a fully automated 
MRI-based glioblastoma survival prediction framework. The survival prediction framework 
includes two representative survival prediction pipelines that combine different feature selection 
and regression approaches. The framework is evaluated using two recent widely used benchmark 
datasets from Brain Tumor Segmentation (BraTS) global challenges in 2017 and 2018.  
 
5.2 GLIOBLASTOMA SURVIVAL PERDITION USING RADIOMICS  
 
In this section, two different survival prediction models are proposed for survival 
prediction. The first model is a tree-based method for overall-survival regression prediction using 
a three-step feature selection and Random forest (RF) regression model (Figure 14.a). The second 
survival prediction model (Figure 14.b) includes a prediction of survival risk classification (short, 
medium, and long-term survival). Subsequently, an overall survival regression is performed based 
on the survival risk class label. Both classification and regression models are trained on 
quantitative- radiomics features obtained from the segmented tumor. The recursive feature 
selection method is used to select the features that are used in the classification model. Finally, 
Cox regression is used as a feature selection method in the overall survival regression model. Three 
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overall regression models are trained: long-regression model, mid-regression model, and short 
regression model.  
 




This study uses BraTS18 training, validation, and testing dataset [123-125, 159], and 
BraTS17 training, validation, and testing datasets for patient survival prediction analysis. Both 
BraTS17 and BraTS18 datasets contain a total of 163 Glioblastoma (high-grade glioma (HGG)) 
cases for training, with overall survival, defined in days, and the age of the patient at diagnosis, 
defined in years. The training dataset provides 4 modalities (T1, post-contrast T1-weighted 
(T1Gd), T2-weighted (T2), T2 Fluid Attenuated Inversion Recovery (FLAIR)) along with the 
ground truth segmentation of multiple abnormal tissues (enhanced (EN), edema (ED), necrosis 
and non-enhanced (NCR/NET)) in the tumor. Overall survival risk is classified into three survival 
groups: long (greater than 15 months), medium (between 10 to 15 months), and short (less than 10 
months). 
 In addition, for validation purposes, we use the validation datasets of BraTS17 and 
BraTS18. BraTS17 validation dataset consists of thirty-three cases while that for BraTS18 consists 
of twenty-eight cases for overall survival prediction purposes. BraTS17 testing dataset consists of 
ninety-five cases while that for BraTS18 offers seventy-seven cases for testing the overall survival 
prediction performance. A total of 135 pre-operative GBM BraTS18 training patients are provided 
by The Cancer Imaging Archive (http://www.cancerimagingarchive.net/). The overall survival 
(OS), age at diagnostic (median age, 59 years; range, 17 – 84 years), and other clinical data, 
molecular mutations, and genomics data are downloaded from the Genomic Data Commons Data 







Figure 14. Glioblastoma Survival Prediction Model Outline using Radiomics. a) The first 
survival prediction model (SP1) pipeline using RF regression classifier, and b) the second survival 





5.3.2 FEATURE EXTRACTION 
 
Feature extraction is the first step in the overall survival prediction task. Different 
quantitative imaging features (of around 31 thousand) are extracted from the different types of 
segmented abnormal tissues (edema, enhanced tumor, and tumor core). These features include 
texture, volumetric and area-related features, histogram-graph features, and Euler characteristics 
(vertices, edges, and faces). The heterogeneity in Glioblastoma may be quantified using texture 
and histogram-graph features while the shape of the tumor may be effectively captured using 
volumetric and Euler characteristic features [74, 76, 160].    
 
TEXTURE FEATURES 
A detailed breakdown of the extracted features is as follows: a total of 1107 texture features 
[127] are computed from the raw MRI sequences and different texture representation of the tumor 
volume. The texture representations of the raw MRI are 1) Texton filters [93] 2) texture-fractal 
characterization using piecewise-triangular prism surface area (PTPSA) [96] modeling, 3) fractal 
characterization of multi-fractional Brownian motion (mBm) [97] modeling, 4) and the Holder 
Exponent [129] modeling. The extracted texture imaging features are described by 1) the 
histogram, 2) the co-occurrence matrix, 3) the neighborhood gray-tone difference matrix, and 4) 
the Size Zone Matrix. Histogram features describe the first-order statistical properties of the image 
[161]. The features (that are described by the co-occurrence matrix) measure the texture of the 
image using Haralick statistical features [162]. The features (that are described by the 
neighborhood gray-tone difference matrix) measure a grayscale difference between pixels with 
certain grayscale and their neighboring pixels [133]. The features (that are described by Size Zone 
Matrix) are estimated using run-length techniques [163]. 
Furthermore, six histogram-based statistics (mean, variance, skewness, kurtosis, energy, 
and entropy) features are extracted from the edema, enhanced tumor and necrosis tissues.  
 
VOLUMETRIC AND AREA-RELATED FEATURES 
Thirteen volume-related features are considered: the volume of the whole tumor, the 
volume of the whole tumor with respect to the brain, the volume of sub-regions (edema, enhanced 
tumor, and necrosis) divided by the whole tumor, the volume of sub-regions (edema, enhanced 
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tumor, and necrosis) divided by the brain, the volumes of the enhanced tumor and necrosis divided 
by the edema, the summation of the volume of the edema and enhanced tumor, the volume of the 
edema divided by the summation of the volume of enhanced tumor and necrosis, and the volume 
of the necrosis divided by the summation of the volume of the edema and enhanced tumor. The 
tumor locations and the spread of the tumor in the brain are computed. Another nine area-related 
properties (area, centroid, perimeter, major axis length, minor axis length, eccentricity, orientation, 
solidity, and extent) are computed from three viewpoints (x, y, and z-axes) of the whole tumor. 
 
HISTOGRAM-GRAPH FEATURES  
A total of 832 features extracted from the histogram graph of the different modalities of 
the whole tumor, edema, enhancing, and necrosis regions. These features represent the frequency 
at different intensity bins (of 11,15, and 23) and the bins of the max frequency.  
 
EULER CHARACTERISTICS 
Finally, we compute the Euler characteristic [164] of the whole tumor, edema, enhancing, 
and necrosis, for each slice. The Euler characteristic features are computed on the tumor curve, at 
100 points, and at 72 different angles. Then, the Euler characteristic features are integrated over 
all slices. As a result, each patient is represented by 4 (whole tumor, edema, enhancing, and 
necrosis) Euler characteristic feature vectors. Each vector has a size of 7200 (100 points × 72 
angles). 
 
5.3.3 SURVIVAL PREDICTION MODELS   
 
Two different survival prediction models are proposed for survival prediction. The first 
model is a tree-based method for overall-survival regression prediction using the Random Forest 
(RF) regression model. We have employed RF due to its efficiency, robustness, and flexibility in 
utilization for both multi-class classification and regression tasks [165]. Additionally, RF does not 
require extensive hyper-parameter tuning and is resilient to overfitting. These traits make RF 
preferable over more common models such as artificial neural networks especially when the 
training data is limited. The complete pipeline for the survival regression using RF is illustrated in 
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 Figure 14.a. This model uses significant, predictive, and important features selected from 
the above-mentioned texture, histogram-graph, and volumetric and area-related features. A three-
step feature selection method is utilized as follows. Univariate Cox regression is fitted on every 
extracted feature, and features with p-value < 0.05 are considered significant. Second, univariate 
Cox regression is fitted on the quantitative copy of the significant features. The quantitative copy 
is obtained by thresholding the significant feature around its median value. The last step is 
performed to ensure that each significant feature is also able to split the data set into long vs. short 
survival. Then, recursive feature selection is applied to the 240 features. Finally, the RF regression 
model with tenfold cross-validation is used to evaluate the model at each iteration.  
The model in Figure 14a is used as a baseline to obtain a second more comprehensive 
survival prediction pipeline as shown in Figure 14.b. We incorporate additional features such as 
Euler characteristics. The features for the updated model are then selected using the recursive 
feature selection method as follows. First, we perform recursive feature selection (RFS1) on the 
Euler features alone. Next, another recursive feature selection (RFS2) on the remaining features 
(texture, volumetric, histogram-graph based) is performed. In addition, the overall-survival 
regression model uses Cox regression to select significant features with a p-value < 0.05. 
Moreover, we introduce a state-of-the-art Extreme Gradient Boosting (XGBoost) [131] based 
regression technique for stepwise survival risk classification and overall-survival regression 
prediction using the selected features. The XGBoost based regression model is applied to each of 
the three groups (short, medium, and long) to obtain survival duration in the number of days, 
respectively. One of the major advantages of XGBoost is utilization of L1 and L2 regularization. 
L1 regularization handles sparsity, whereas L2 regularization reduces overfitting [131]. It is worth 
noting that we have not utilized any neural network models for the survival prediction because the 
sample size in this study is not large enough to ensure good training in a neural network setting. 
 
5.4 OVERALL SURVIVAL PREDICTION FRAMEWORK EVALUATION  
 
The proposed framework consists of two distinct radiomics based automated survival 
prediction pipelines. Accordingly, we obtain extensive performance evaluation using two 
pipelines: the first one comprises three-step feature selection and the RF-based survival prediction 
method (henceforth referred to as SP1), while the second consists of XGBoost based survival 
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prediction algorithm (henceforth referred to as SP2). We first participated in the BraTS 2017 
challenge, and the specific combination of machine learning methods with RF survival prediction 
model (known as SP1) offered the best overall performance in this challenge. We subsequently 
participated in the BraTS 2018 challenge, and the augmented model (known as SP2) offered the 
best performance using the validation dataset.  
 
 
Table 10. Performance of SP1, SP2, and modified-SP2 methods with BratS17 and 
BraTS18 datasets. The evaluation of validation is performed using the online evaluation platform 
of CBICA IPP (https://ipp.cbica.upenn.edu).
 Survival Prediction Performance 
Model/Dataset Accuracy Mean Square Error 
SP1/ BraTS17 training 0.67 78,929 
SP1/ BraTS17 validation 0.667 209,908 
SP1/ BraTS17 test 0.579 245,780 
SP2/ BraTS18 training 0.73 91,585 
SP2/ BraTS18 validation 0.679 153,466 
SP2/ BraTS18 test 0.519 367,240 
RF-SP1/ BraTS18 validation 0.464 170,737 
XGBoost-SP2/ BraTS17 validation 0.636 218,097 
Modified-SP2/ BraTS18 training 0.718 99,358 
Modified-SP2/ BraTS18 validation 0.679 127,697 
 
 
For SP1 the survival prediction features are the age and 40 texture and volumetric features. 
The distribution of the 40 features is as follows: 12 features extracted from Texton of the tumor, 9 
features extracted from the Holder exponent representations of the tumor, 6 features represent the 
histogram of the abnormal tissues, 5 from the raw MR modality of the tumor and sub-regions, 4 
describe the volume of the tumor and the sub-regions, and 4 features are extracted from the tumor 
area and major axis length. 
In comparison, as discussed above and shown in Figure 14.b for SP2, all relevant features 
are extracted from the ground truth cases available with the BraTS18 training dataset. The 
subsequent recursive feature selection for Euler features (28 thousand) alone generates 39 features. 
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The distribution of the 39 Euler features includes 16 features computed around the contour of ET, 
16 features computed around that of WT, and 7 features computed around that of edema, 
respectively. The application of recursive feature selection on the remaining features produces an 
additional 23 texture features, 4 histogram graph features, and 8 area features of the edema, ET, 
and WT, respectively. The XGBoost with leave-one-out cross-validation (LOOCV) is employed 
on the selected 74 features and the age to predict three corresponding survival classes (short, 
medium, long). This yields a classification accuracy of 0.73 (95% confidence intervals [CI]: 0.655-
0.797) for the BraTS18 training dataset.  
 
 
Table 11. Confusion matrix of SP1, SP2, and modified-SP2, and some statistics derived 
from the confusion matrix based on each survival label in the training model. 
 
 
SP1 2017 SP2 2018 Modified-SP2 2018 
 Reference Reference Reference 
Predictions Long Med Low Long Med Low Long Med Low 
Long 32 7 10 43 13 4 44 11 4 
Med 24 34 12 5 18 3 7 18 6 
Low 0 1 43 8 11 58 5 13 55 
Total number of cases 56 42 65 56 42 65 56 42 65 
Statistics SP1 2017 SP2 2018 Modified-SP2 2018 
Sensitivity 0.571 0.810 0.662 0.768 0.429 0.892 0.786 0.429 0.846 
Specificity 0.841 0.702 0.990 0.841 0.934 0.806 0.860 0.886 0.816 
Balanced Accuracy (Sen. + Spec.)/2 0.706 0.756 0.826 0.804 0.681 0.849 0.823 0.657 0.831 
Positive Prediction Value (PPV) 0.653 0.486 0.977 0.717 0.692 0.753 0.745 0.581 0.753 
Negative Prediction Value (NPV) 0.789 0.914 0.815 0.874 0.825 0.919 0.885 0.817 0.889 
 
 
First, we establish the performance of both SP1 and SP2 methods using the BraTS17 and 
BraTS18 training and validation datasets. The training dataset performance is obtained through 
leave-one-out cross-validation analysis. The performance evaluation of methods using BraTS 
validation datasets is restricted to the online evaluation platform of the organizer of the BraTS 
challenge (CBICA IPP at https://ipp.cbica.upenn.edu) and must be performed during a specific 
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time period during the challenge. Note that the second pipeline (SP2) is developed after the BraTS 
2017 challenge is concluded; hence, the 2017 validation portal is no longer available for 
evaluation. However, a fair comparison between the pipelines can still be obtained through the 
training data evaluations and the validation evaluations of respective challenge years. The results 
are summarized in Table 10 and Table 11. 
 
 
Table 12. Performance of LOOCV of the three regression models in SP2 and modified-

























294.177 86,540 217.714 302.069 91,246 209.253 
Medium-
regression model 
35.629 1,269 28.190 40.702 1,657 34.971 
Short-regression 
model 
61.449 3,776 50.402 80.340 6,455 65.094 
 
 
The results in Table 10 for training and validation illustrate that the SP2 model offers better 
performance in accuracy over that of the SP1 model. The SP2 model also obtains improvement 
over SP1 in validation MSE. Note, the SP1 model has been ranked the first in the BraTS 2017 
challenge for survival prediction category among seventeen teams globally. The overall high MSE 
for survival prediction is particularly due to the wide range within the long-term survival category 
resulting in large prediction errors. Further note that the MSE of SP2 for BraTS18 training is the 
sum of the three MSE (Table 12) values obtained for the short-, medium-, and long-regression 
models shown in Table 12. Finally, the test results for both SP1 for BraTS17 and SP2 for BraTS18 
in Table 10 show that SP1 performed better in patient-survival prediction than that for SP2. This 




5.4.1 COMPARATIVE EVALUATION OF SURVIVAL PREDICTION 
PERFORMANCE WITH SP1 AND SP2 
 
Table 11 shows the confusion matrix of both SP1 and SP2 and relevant statistics for each 
class in the classification training model for survival risk prediction. The sensitivity and balanced 
accuracy of the medium survival group in SP2 is the lowest when compared to the other two 
survival groups. The top four important features as ranked by XGBoost are tumor extent in the z-
axis, the width of the enhanced tumor computed from x-axis point of view, and contour around the 
edema contour and enhanced tumor. The mean value of each of the four features is able to 
significantly (p-value < 0.05) stratify the 163 cases into two risk groups (low-risk and high-risk) 
as illustrated in Figure 15.  
Our analysis of Figure 15 reveals that thresholding the value of features around the mean 
can stratify the 163 cases significantly (log-rank test, p-value < 0.05) into two survival groups. The 
features and the median survival of each group are: 
• the tumor extent from z-axis viewpoint stratifies the 163 cases into two groups with a median 
survival of 394 days vs 318 days,  
• the enhanced tumor width from x-axis viewpoint stratifies the 163 cases into two groups with 
a median survival of 437 days vs 268 days, 
• the contour around the edema stratifies the 163 cases into two groups with a median survival 
of 387 days vs 330 days, 
• and contour around the enhanced tumor stratifies the 163 cases into two groups with a median 
survival of 421 days vs 278 days.  
The second step in the survival prediction is to obtain individual regression training models 
corresponding to the short, medium, and long survival classes. These short-, medium-, and long-
regression models use features selected distinctly for each survival class using Cox regression 
(with p-value < 0.05). The number of significant features selected for the short-, medium-, and 
long-regression models is 83, 51, and 148, respectively. Table 12 illustrates the performance of 
LOOCV with XGBoost for the selected features using specified survival risk cases in BraTS18 
training cases. 
Note that the wide range of the overall survival of the long-survival group (greater than 15 
months) may cause the RMSE of the long-regression model to have the highest RMSE (Table 12). 
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This also may cause a high mean square error when using the validation dataset (Table 10). The 
range of the overall survival of the short-survival group is 10 months, whereas the medium-




In order to reduce the high dimensionality of the features in SP2 classification and 
regression steps, we modify SP2 in Figure 14.b as follows: 1) calculate and rank the feature 
importance for each classification and regression model; 2) select features that have relative scaled 
importance greater than 50%; 3) train the modified selected features in a new classification and 
regression training models utilizing XGBoost. The resulting 30 significant features are applied in 
the classification step of the modified-SP2. The distribution of these features is as follows: 13 
features represent Euler characteristics, 7 features represent volumetric and area-related properties, 
4 histogram-graph based features, 5 texture features, and one feature with age information. 
The number of significant features used in the short-, medium-, and long-regression models 
of the modified-SP2 is 11, 9, and 11, respectively. The distribution of the features in the modified 
short-regression model is as follows: 2 volumetric and area-related features, 1 histogram-graph 
based features, 7 texture features, and one feature with age information. The features employed in 
the modified med-regression model are 5 volumetric and area-related features, 3 texture features, 
and Age. The features of the modified long-regression model are 2 volumetric and area-related 
features, 8 texture features, and one feature with age information. 
The modified-SP2 achieves cross-validated accuracy of 0.718 as illustrated in Table 10. 
Table 11 illustrates the statistics of its confusion matrix in the classification training model. Table 
12 illustrates the performance of the modified regression training models. Additionally, the 
modified-SP2 is validated using the BraTS18 validation set, and its performance is illustrated in 
Table 10. Note that the different performances of SP2 and modified-SP2 are almost similar when 
using the BraTS18 training and validation dataset statistics of each class in SP2 and the modified-
SP2 are almost similar. This can be explained by the fact that XGBoost provides L1 and L2 
regularization. Additionally, the modified-SP2 is validated using the BraTS18 validation set, and 








Figure 15. Kaplan Meier of the top four important features used in SP2. The features are 
divided around its mean value to stratify the 163 subjects into two groups: high risk group (red line), 
and low risk group (blue line). The features are (a) tumor extent; (b) the enhanced tumor width; (c) 
contour around the edema; and (d) contour around the enhanced tumor. The shaded area indicates 












5.5 CRITICAL ANALYSIS OF FEATURES UTILIZED IN THE SURVIVAL 
PREDICTION PIPELINES 
 
This section provides a critical analysis of the features and their effects on survival 
prediction performance. As mentioned in the previous sections, the features that are derived from 
different abnormal tissue types in the tumor of the segmented tumor region significantly contribute 
to the survival prediction performance. Accordingly, we visualize the features extracted from 
different abnormal tissue types of the segmented tumor. The visualization is performed using one 
of the most widely-used high-dimensional data visualization techniques known as t-Distributed 
Stochastic Neighbor Embedding [132] (t-SNE). First, t-SNE is used to explore the features 
obtained from different abnormal tissue types from the segmented tumor region and analyze the 
effects of these features on the performance of the survival prediction task using the BraTS 2017 
and BraTS 2018 dataset.  
For the SP1 pipeline, we extract a total of 40 features from the sub-tissue types of the 
segmented tumor region. The features extracted in SP1 are as follows: 36 features for the whole 
tumor, 2 features for the enhanced tumor, and 2 features for edema. We visualize the feature 
clusters for patient survival categories: long, medium, and short term. In this case, we consider all 
40 features obtained from the 163 BraTS17 training data as mentioned above and explore the 
grouping against the tumor risk labels using the t-SNE technique. Figure 16 shows the visualization 
of the corresponding features for long, medium, and short risk labels. Note that all the visualization 
outcomes shown are obtained after extensive hyper-parameter tuning of t-SNE to produce the best 
possible results. Figure 16 demonstrates that though there is some separation of corresponding 
features between the long and short categories, the medium category is mixed with both long and 
short categories. This suggests that it is still difficult to visualize a clear separation of extracted 
features for the survival prediction task with the available patient dataset for this study. The 
corresponding survival prediction performance of the SP1 pipeline using the testing dataset is as 
shown in Table 10 and Table 12. As mentioned above, though the SP1 pipeline was ranked first 
place in the BraTS 2017 challenge, the feature distribution in Figure 16 suggests an inherent 
challenge in extracting representative features for the survival prediction task. 
Next, we explore the features and their effects on the performance of our SP2 pipeline 
using the BraST18 dataset. We extract a total of 74 features and the age for the SP2 pipeline. The 
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features extracted in SP2 are as follows: 43 features for the whole tumor, 22 features for the 
enhanced tumor, 8 features for edema, and 1 feature for necrosis. Figure 17 shows the visualization 
of the 74 features in terms of long, medium, and short risk labels using the 163 sample BraTS18 
training data. Our analysis suggests that the tSNE technique again fails to group the features in 
long, medium, and short categories. Though there is some separation between the corresponding 
features for long and short categories, the features for the medium category mix with both short 
and long categories for multiple subjects, quite similar to the visualization of SP1. This poor 
separation may still be due to the lack of sufficient representative strength of the features for 
categorizing different risk labels. Consequently, Table 10 shows that our proposed SP2 pipeline 









Figure 16. SP1 feature visualization. (a) The 3D; and (b) the 2D plot of t-Distributed 
Stochastic Neighbor Embedding (t-SNE) of the selected features of SP1 clustered based on the long, 








Figure 17. SP2 feature visualization. (a) The 3D plot of the t-Distributed Stochastic 
Neighbor Embedding (t-SNE) of the selected features of SP2 clustered based on the long, medium, 
and short risk labels using BraTS18 training dataset. (b) The 2D plot of the same training dataset. 
 
 
Additionally, we validate our RF survival prediction in SP1 (RF-SP1) using the BraTS18 
validation set. We also validate XGBoost survival prediction in SP2 (XGBoost-SP2) using the 
BraTS17 validation dataset. The results are summarized in Table 1. Using the BraTS17 validation 
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dataset, the RF-SP1 model achieves 67.7% accuracy, whereas the XGBoost-SP2 model achieves 
63.6%. Using the BraTS18 validation dataset, the RF-SP1 model achieves 46.4% accuracy, 
whereas the XGBoost-SP2 model achieves 67.9% accuracy. These results indicate that the 
XGBoost-SP2 combination performs considerably better than that of the RF-SP1 with the 
BraTS18 dataset and reasonably well with the BraTS17 dataset, respectively. Note that the ground 
truth of the BraTS17 and BraTS18 validation dataset is not provided. As a result, we have 
segmented the BraTS17 and BraTS18 validation dataset using the semantic label fusion model of 
CNN and RF [95] and the semantic label fusion of U-Net and FCN [92], respectively.  
 
5.6 COMPARISON OF SURVIVAL PREDICTION WITH STATE-OF-THE-ART 
WORKS 
 
Comparison of the proposed survival prediction pipelines SP1 and SP2 with some of the 
state-of-the-art methods in the literature is discussed next. Table 13 summarizes the performances 
of these state-of-the-art models and presents a comparison with our proposed framework (SP2). 
Reference [166] proposes using histogram features extracted from denoised MR images (by using 
2 levels of the Daubechies wavelet transform) in a support vector machine to predict overall 
survival. Their method achieves a 10-fold cross-validation accuracy of 0.667 using the BraTS17 
training dataset. Reference [167] extracts volumetric, spatial, morphological, and tractography 
features from MR images. Feature normalization and selection is performed, and the selected 
features are trained in a support vector machine model. Their proposed model achieves an accuracy 
of 0.7 using the BraTS18 training dataset and an accuracy of 0.5 using the BraTS18 validation 
dataset. Reference [168] utilizes volumetric features along with Random Forest to predict overall 
survival. Their method achieves five-fold cross-validation accuracy of 0.638 using the BraTS17 
training dataset. The results demonstrate that our proposed framework achieves higher accuracy 
in overall survival prediction compared to the current-state-of-the-art models applied to the same 
datasets. Note, unlike our proposed SP1 and SP2 pipelines, the reported performance for all these 




Table 13. Comparison of our proposed survival prediction pipeline with state-of-the-art 
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This work proposes a novel framework for fully automated radiomics-based Glioblastoma 
survival prediction. The overall framework is designed as a two-step process where feature 
selection is carried out in the first step, and then the survival prediction is carried out in the second 
step. The framework includes two survival prediction algorithms SP1 and SP2, represented using 
feature types, feature selection, regression, and classification methods.  
The primary survival pipeline (SP1) combines three-step feature selection and the RF-
based survival prediction algorithm to obtain the final output. The second pipeline (SP2) consists 
of XGBoost based survival prediction algorithm. As shown in Table 10 and Table 13 the pipelines 
used in both SP2 and SP1 offer a comparative survival prediction performance. The functionality 
of SP2 is further enhanced by using additional features extracted from the sub-tissues (edema, 
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enhanced tumor, and necrosis) and a two-step classification and regression method. Different 
studies [158, 169-171] correlate between survival prediction in glioblastoma and different sub-
tissues. SP2 shows improvements over our primary survival prediction model (SP1) [91] with 
LOOCV accuracy increase to 0.73 from 0.67 for training datasets, whereas the modified-SP2 






SUMMARY AND FUTURE WORK 
 
6  
Computational modeling for non-invasive methods that analyze clinical outcomes for 
patients has emerged as a vital and promising body of research. For example, these non-invasive 
methods are important in tumor progression analysis and classification of molecular mutations in 
diffuse gliomas prior to invasive tissue sampling. Radiomics may be used to quantify tumor 
heterogeneity that varies between patients and even within a patient. Consequently, radiomics has 
an essential role in current radiology practice such as disease diagnosis, monitoring, and treatment 
planning. This dissertation proposes computational models for non-invasive survival prediction, 
molecular classification, and grading prediction based on radiomics and clinical data for diffuse 
glioma patients.  Furthermore, statistical models are proposed for molecular mutation classification 
and grading based on genomics count-based data and radiomics utilizing the negative binomial 
regression. To evaluate the efficacy of the proposed methods discussed in this dissertation, we 
cross-validate, test, and compare the performance with state-of-the-art methods.  
In Chapter 3, we investigate the efficacy of our novel fractal and multi-resolution fractal 
radiomics features on the performance of the non-invasive prediction of molecular mutation in 
diffuse LGG. We address diffuse LGG molecular grading and classification using radiomics 
features extracted from multimodality MRI of the segmented tumor volume. The extracted 
radiomics features describe the multi-resolution fractal modeling, texture features, volumetric, and 
area-based characteristics. In the LGG molecular grading and classification model, different 
molecular (IDH, 1p/19q codeletion, ATRX, and TERT), and MGMT methylation prediction models 
are introduced. Our analysis of the MGMT classification reveals that the less aggressive 
methylated MGMT status associates significantly with higher values of the histogram entropy (i.e., 
uncertainty) of tumor mBm and carries HR of 0.579 per standard deviation (likelihood ratio test 
p-value = 0.035). The study further shows that the highly aggressive MGMT un-methylated LGG 
associates with the higher values of the size ratio between enhanced tumor and necrosis. The 
histogram entropy of tumor mBm and the size ratio between enhanced tumor and necrosis are 
among the most predictive features of MGMT methylation status. Our IDH mutation classification 
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indicates that the tumor correlation associates significantly with mutated IDH and the complexity 
of HE of the enhanced tumor associates significantly with WT IDH status. Furthermore, our 
analysis reveals that the size ratio between the enhanced tumor and necrosis is a significant 
predictor feature of the IDH status which is also a significant predictor of MGMT status. 
Furthermore, our analysis of the 1p/19q codeletion classification model indicates that the location 
of the upper-left necrosis bounding box and horizontal coordinate of the necrosis centroid are 
among the most predictive features and that high values of histogram entropy of tumor mBm 
associate significantly with the existence of 1p/19q codeletion. Our analysis of the ATRX status 
classification model reveals that the tumor information-measure of correlation and the mean of the 
tumor histogram are the most frequently selected features and that the higher values of 
information-measure of correlation are associated significantly with WT ATRX. Moreover, the 
TERT classification model analysis shows that tumor information-measure of correlation and the 
upper-left coordinate in the edema bounding box are the most frequently selected features. Higher 
values of these two features are significantly associated with mutated TERT status. In addition, our 
analysis suggests that the higher values of the inverse difference moment of HE associates 
significantly with WT TERT and offers HR = 0.612 per standard deviation (likelihood ratio test, 
p-value = 0.03). High values of the inverse difference moment of an HE tumor predict the less 
aggressive WT TERT. Finally, our molecular mutations classification models reveal that fractal 
features significantly affect MGMT, IDH, 1p/19q co-deletion, and ATRX prediction models. 
Features analysis and the performance of the molecular mutations classification models in Table 
2 confirm our hypothesis by showing the importance of the fractal features in diffuse LGG 
molecular mutations prediction. 
A thorough study utilizing the genomics count-based data along with radiomics in a 
negative binomial regression model (i.e., radiogenomics-NB) is discussed in Chapter 4. We 
employ both RNAseq counts data and radiomics features to perform molecular mutations 
classification and prediction in diffuse LGG. The NB distribution is proposed to model RNAseq 
counts data, and the log-linear regression model is utilized to model the relationship between the 
estimated model mean and radiomics. The proposed radiogenomics-NB model preserves the 
count-based nature of RNAseq data, fuse radiomics and RNAseq counts data, and develop a 
complete radiogenomics-NB model with better characterization of patient data. This study 
investigates three radiogenomics-NB molecular mutation models; IDH mutation, 1p/19q 
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codeletion, and ATRX mutation. We investigate the efficacy of using the top different number of 
DERs. Our analysis reveals the best performance of the radiogenomics-NB models is achieved 
using 10 DERs. Moreover, we investigate the gender-specific effect on the radiogenomics-NB 
models. Our analysis reveals that female-specific radiogenomics-NB models significantly 
outperform the male-specific radiogenomics-NB models for prediction of IDH status, 1p/19q 
codeletion, and ATRX status, respectively. Additionally, we compare our radiogenomics-NB 
model to NBLDA, RF-genomics, FR-radiogenomics, and VoomNSC. Our model significantly 
outperforms NBLDA, RF-genomics, and VoomNSC for prediction of IDH and ATRX mutations, 
which indicates the power of fusing radiomics into genomics data to develop classification and 
prediction models. 
Furthermore, in Chapter 5, a fully automated radiomics-based overall survival prediction 
framework for glioblastoma patients is discussed. The overall survival prediction framework 
comprises two different pipelines that combine different feature selection and regression 
approaches. The survival prediction framework is assessed using two recent widely used 
benchmark datasets: BraTS17 and BraTS18. The framework predicts the overall survival in days 
and classifies the overall survival risk into three survival groups: long (greater than 15 months), 
medium (between 10 to 15 months), and short (less than 10 months). Our analysis using the t-SNE 
tool reveals that selected features are able to separate between the long- and short-term survival 
categories, while the medium-term survival category is mixed with both long and short categories. 
This poor separation of the medium category may still be due to the lack of the sufficient 
representative strength of the radiomics for categorizing different risk labels The performances of 
the overall survival pipelines (SP1 and SP2) demonstrate that our proposed framework achieves 
higher accuracy in overall survival prediction compared to the current-state-of-the-art models 
applied to the same datasets. The proposed pipeline SP1 achieves the best performance in the 
BraTS 2017 in the survival prediction task. 
 
6.1 FUTURE WORK 
 
The analysis of glioma survival prediction and molecular mutations classification and 
predictions that are discussed in this dissertation show competitive performance when compared 
with the state-of-the-art methods. However, there are a few limitations to this work. Future studies 
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are necessary to address these limitations and enhance the performance of the glioma outcome 
analysis and prediction models proposed in this work. Future studies are necessary for the following 
areas. In Chapter 3, the performances of the proposed LGG molecular mutation classification and 
prediction model show promise when compared to different methods and models in the literature. 
In the study, we target radiomics features in LGG patients. These molecular mutations are not 
carried by LGG patients only. Therefore, in the future, a full-scale study of a more diverse dataset 
of glioma patients (not only LGG patients) may reflect higher reliability of the performance of the 
proposed molecular mutations prediction model. Additionally, utilizing important clinical data 
(e.g., age at diagnosis, gender, ethnicity, tumor morphology, and Karnofsky Status) along with the 
existing radiomics may offer more powerful non-invasive molecular mutation classifying models.  
In Chapter 4, we propose volumetric radiomics in the radiogenomics-NB model. However, 
different mutations may be better predicted in the radiogenomics-NB model using different clinical 
information and/or radiomics. In the future, a superior framework/mechanism is needed to 
investigate a specific radiomics and associate them with the different mutations and their RNAseq 
read counts data through the NB model. Moreover, in the derivation of the radiogenomics-NB 
model, we assume that all RNAseq are independent of each other. This assumption may not always 
be realistic, and gene interaction may affect a certain glioma outcome. Therefore, it is necessary to 
consider the gene interaction effect to extend the radiogenomics-NB model.     
Even though in Chapter 5, the SP1 ranked first in the BraTS 2017 challenge and SP2 
achieved a competitive performance, there are a few limitations of the proposed models. First, the 
total number of cases for the survival training dataset is 163, and both BraTS 2017 and BraTS 
2018 required that the data must be divided into three separate survival groups. Consequently, the 
number of training cases are divided among three groups as follows: 65 cases for short, 42 cases 
for medium and 56 cases for the long survival group, respectively. Therefore, future work includes 
a larger dataset for training each regression model to improve model performance. Second, this 
study may benefit from additional clinical data such as gender, race, and Karnofsky Status to 
strengthen the reliability of the different survival regression and classification models. Finally, the 
overall survival risk classification performance of the state-of-the-art methods in the literature, 
including the pipelines proposed in this work, may be improved further. The visualization of 
survival features suggests the difficulty in separating the high dimensional data into the three 
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distinctive risk classes. In addition, there is a need for further research in fusing clinical data with 
radiomics and novel feature engineering for survival prediction. 
Finally, the work in this dissertation mainly presents multiple models for glioma outcome 
survival analysis and prediction, and molecular mutations classification. However, the therapeutic 
outcome prediction requires a careful investigation of the imaging changes before and after the 
therapeutic session in a proper computational machine learning model. Furthermore, to develop a 
full and robust clinical outcome framework, the therapeutic outcome should be assessed and 
predicted. Such a study requires an understanding of the therapeutic modality and the relevant 
clinical data (e.g. age, gender, the severity of the tumor), radiomics (e.g., tumor volume, tumor 
location, the proportion of necrosis), and genomics (e.g., existed mutations), and other omics data 





[1] Q. T. Ostrom et al., "CBTRUS Statistical Report: Primary Brain and Other Central 
Nervous System Tumors Diagnosed in the United States in 2012–2016," Neuro-oncology, 
vol. 21, no. Supplement_5, pp. v1-v100, 2019. 
[2] A. Volterra and C. Steinhäuser, "Glial modulation of synaptic transmission in the 
hippocampus," Glia, vol. 47, no. 3, pp. 249-257, 2004. 
[3] G. M. Cooper, R. E. Hausman, and R. E. Hausman, The cell: a molecular approach. ASM 
press Washington, DC, 2000. 
[4] C. Walker, A. Baborie, D. Crooks, S. Wilkins, and M. Jenkinson, "Biology, genetics and 
imaging of glial cell tumours," The British journal of radiology, vol. 84, no. 
special_issue_2, pp. S90-S106, 2011. 
[5] D. N. Louis et al., "The 2007 WHO classification of tumours of the central nervous 
system," Acta neuropathologica, vol. 114, no. 2, pp. 97-109, 2007. 
[6] P. Kleihues, P. C. Burger, and B. W. Scheithauer, "The new WHO classification of brain 
tumours," Brain pathology, vol. 3, no. 3, pp. 255-268, 1993. 
[7] A. Claes, A. J. Idema, and P. Wesseling, "Diffuse glioma growth: a guerilla war," Acta 
neuropathologica, vol. 114, no. 5, pp. 443-458, 2007. 
[8] D. N. Louis, "The next step in brain tumor classification:“Let us now praise famous 
men”… or molecules?," ed: Springer, 2012. 
[9] A. Korshunov et al., "Integrated analysis of pediatric glioblastoma reveals a subset of 
biologically favorable tumors with associated molecular prognostic markers," Acta 
neuropathologica, vol. 129, no. 5, pp. 669-678, 2015. 
[10] N. Nonoguchi, T. Ohta, J.-E. Oh, Y.-H. Kim, P. Kleihues, and H. Ohgaki, "TERT promoter 
mutations in primary and secondary glioblastomas," Acta neuropathologica, vol. 126, no. 
6, pp. 931-937, 2013. 
[11] D. N. Louis et al., "International Society of Neuropathology‐Haarlem consensus guidelines 
for nervous system tumor classification and grading," Brain pathology, vol. 24, no. 5, pp. 
429-435, 2014. 
[12] D. N. Louis et al., "The 2016 World Health Organization classification of tumors of the 




[13] H. Ohgaki and P. Kleihues, "Population-based studies on incidence, survival rates, and 
genetic alterations in astrocytic and oligodendroglial gliomas," Journal of Neuropathology 
& Experimental Neurology, vol. 64, no. 6, pp. 479-489, 2005. 
[14] A. Mukasa et al., "Significance of IDH mutations varies with tumor histology, grade, and 
genetics in Japanese glioma patients," Cancer science, vol. 103, no. 3, pp. 587-592, 2012. 
[15] H. Yan et al., "IDH1 and IDH2 mutations in gliomas," New England Journal of Medicine, 
vol. 360, no. 8, pp. 765-773, 2009. 
[16] A. L. Cohen, S. L. Holmen, and H. Colman, "IDH1 and IDH2 mutations in gliomas," 
Current neurology and neuroscience reports, vol. 13, no. 5, p. 345, 2013. 
[17] J.-R. Chen, Y. Yao, H.-Z. Xu, and Z.-Y. Qin, "Isocitrate dehydrogenase (IDH) 1/2 
mutations as prognostic markers in patients with glioblastomas," Medicine, vol. 95, no. 9, 
2016. 
[18] C. Hartmann et al., "Patients with IDH1 wild type anaplastic astrocytomas exhibit worse 
prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the 
unfavorable prognostic effect of higher age: implications for classification of gliomas," 
Acta neuropathologica, vol. 120, no. 6, pp. 707-718, 2010. 
[19] N. Hu, R. Richards, and R. Jensen, "Role of chromosomal 1p/19q co-deletion on the 
prognosis of oligodendrogliomas: A systematic review and meta-analysis," 
Interdisciplinary Neurosurgery, vol. 5, pp. 58-63, 2016. 
[20] J. E. Eckel-Passow et al., "Glioma groups based on 1p/19q, IDH, and TERT promoter 
mutations in tumors," New England Journal of Medicine, vol. 372, no. 26, pp. 2499-2508, 
2015. 
[21] J. Schwartzentruber et al., "Driver mutations in histone H3. 3 and chromatin remodelling 
genes in paediatric glioblastoma," Nature, vol. 482, no. 7384, pp. 226-231, 2012. 
[22] Y. Jiao et al., "Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification 
of malignant gliomas," Oncotarget, vol. 3, no. 7, p. 709, 2012. 
[23] H. E. Leeper, A. A. Caron, P. A. Decker, R. B. Jenkins, D. H. Lachance, and C. Giannini, 
"IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas," Oncotarget, 
vol. 6, no. 30, p. 30295, 2015. 
[24] J. F. Costello, B. W. Futscher, K. Tano, D. M. Graunke, and R. O. Pieper, "Graded 
methylation in the promoter and body of the O6-methylguanine DNA methyltransferase 
96 
 
(MGMT) gene correlates with MGMT expression in human glioma cells," Journal of 
Biological Chemistry, vol. 269, no. 25, pp. 17228-17237, 1994. 
[25] S. Leu et al., "IDH/MGMT-driven molecular classification of low-grade glioma is a strong 
predictor for long-term survival," Neuro-oncology, vol. 15, no. 4, pp. 469-479, 2013. 
[26] K. Zhang, X.-q. Wang, B. Zhou, and L. Zhang, "The prognostic value of MGMT promoter 
methylation in Glioblastoma multiforme: a meta-analysis," Familial cancer, vol. 12, no. 3, 
pp. 449-458, 2013. 
[27] A. M. Rutman and M. D. Kuo, "Radiogenomics: creating a link between molecular 
diagnostics and diagnostic imaging," European journal of radiology, vol. 70, no. 2, pp. 
232-241, 2009. 
[28] N. Just, "Improving tumour heterogeneity MRI assessment with histograms," British 
journal of cancer, vol. 111, no. 12, pp. 2205-2213, 2014. 
[29] L. S. Hu et al., "Multi-parametric MRI and texture analysis to visualize spatial histologic 
heterogeneity and tumor extent in glioblastoma," PloS one, vol. 10, no. 11, p. e0141506, 
2015. 
[30] H. Itakura et al., "Magnetic resonance image features identify glioblastoma phenotypic 
subtypes with distinct molecular pathway activities," Science translational medicine, vol. 
7, no. 303, pp. 303ra138-303ra138, 2015. 
[31] D. Yang, G. Rao, J. Martinez, A. Veeraraghavan, and A. Rao, "Evaluation of tumor‐
derived MRI‐texture features for discrimination of molecular subtypes and prediction of 
12‐month survival status in glioblastoma," Medical physics, vol. 42, no. 11, pp. 6725-6735, 
2015. 
[32] R. Brown et al., "The use of magnetic resonance imaging to noninvasively detect genetic 
signatures in oligodendroglioma," Clinical Cancer Research, vol. 14, no. 8, pp. 2357-2362, 
2008. 
[33] W. L. Bi and R. Beroukhim, "Beating the odds: extreme long-term survival with 
glioblastoma," Neuro-Oncology, vol. 16, no. 9, p. 1159, 2014. 
[34] H. Ohgaki and P. Kleihues, "The definition of primary and secondary glioblastoma," 
Clinical cancer research, vol. 19, no. 4, pp. 764-772, 2013. 
97 
 
[35] J. P. O'Connor, C. J. Rose, J. C. Waterton, R. A. Carano, G. J. Parker, and A. Jackson, 
"Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical 
outcome," Clinical Cancer Research, vol. 21, no. 2, pp. 249-257, 2015. 
[36] Y. Liu, X. Xu, L. Yin, X. Zhang, L. Li, and H. Lu, "Relationship between glioblastoma 
heterogeneity and survival time: An MR imaging texture analysis," American Journal of 
Neuroradiology, vol. 38, no. 9, pp. 1695-1701, 2017. 
[37] D. Molina et al., "Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: 
a potential marker of survival," The British journal of radiology, vol. 89, no. 1064, p. 
20160242, 2016. 
[38] J. P. O'Connor et al., "Imaging biomarker roadmap for cancer studies," Nature reviews 
Clinical oncology, vol. 14, no. 3, p. 169, 2017. 
[39] R. Weissleder, M. C. Schwaiger, S. S. Gambhir, and H. Hricak, "Imaging approaches to 
optimize molecular therapies," Science translational medicine, vol. 8, no. 355, pp. 
355ps16-355ps16, 2016. 
[40] R. J. Gillies, P. E. Kinahan, and H. Hricak, "Radiomics: images are more than pictures, 
they are data," Radiology, vol. 278, no. 2, pp. 563-577, 2015. 
[41] A. Giardino et al., "Role of imaging in the era of precision medicine," Academic radiology, 
vol. 24, no. 5, pp. 639-649, 2017. 
[42] G. S. Ginsburg and H. F. Willard, "Genomic and personalized medicine: foundations and 
applications," Translational research, vol. 154, no. 6, pp. 277-287, 2009. 
[43] F. Meric-Bernstam, C. Farhangfar, J. Mendelsohn, and G. B. Mills, "Building a 
personalized medicine infrastructure at a major cancer center," Journal of Clinical 
Oncology, vol. 31, no. 15, p. 1849, 2013. 
[44] W. K. Redekop and D. Mladsi, "The faces of personalized medicine: a framework for 
understanding its meaning and scope," Value in Health, vol. 16, no. 6, pp. S4-S9, 2013. 
[45] T. W. Hakkarainen, N. M. Kopari, T. N. Pham, and H. L. Evans, "Necrotizing soft tissue 
infections: review and current concepts in treatment, systems of care, and outcomes," 
Current problems in surgery, vol. 51, no. 8, pp. 344-362, 2014. 
[46] J. Wu, K. K. Tha, L. Xing, and R. Li, "Radiomics and radiogenomics for precision 
radiotherapy," Journal of radiation research, vol. 59, no. suppl_1, pp. i25-i31, 2018. 
98 
 
[47] E. Sala et al., "Unravelling tumour heterogeneity using next-generation imaging: 
radiomics, radiogenomics, and habitat imaging," Clinical radiology, vol. 72, no. 1, pp. 3-
10, 2017. 
[48] M. D. Kuo and N. Jamshidi, "Behind the numbers: decoding molecular phenotypes with 
radiogenomics—guiding principles and technical considerations," Radiology, vol. 270, no. 
2, pp. 320-325, 2014. 
[49] H. Itakura et al., "Magnetic resonance image features identify glioblastoma phenotypic 
subtypes with distinct molecular pathway activities," Science translational medicine, vol. 
7, no. 303, 2015. 
[50] J. Wu et al., "Unsupervised clustering of quantitative image phenotypes reveals breast 
cancer subtypes with distinct prognoses and molecular pathways," Clinical Cancer 
Research, vol. 23, no. 13, pp. 3334-3342, 2017. 
[51] D. Fehr et al., "Automatic classification of prostate cancer Gleason scores from 
multiparametric magnetic resonance images," Proceedings of the National Academy of 
Sciences, vol. 112, no. 46, pp. E6265-E6273, 2015. 
[52] P. Kickingereder et al., "Radiogenomics of glioblastoma: machine learning–based 
classification of molecular characteristics by using multiparametric and multiregional MR 
imaging features," Radiology, vol. 281, no. 3, pp. 907-918, 2016. 
[53] M. A. Mazurowski, K. Clark, N. M. Czarnek, P. Shamsesfandabadi, K. B. Peters, and A. 
Saha, "Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is 
associated with tumor genomic subtypes and patient outcomes in a multi-institutional study 
with The Cancer Genome Atlas data," Journal of neuro-oncology, vol. 133, no. 1, pp. 27-
35, 2017. 
[54] S. Rathore et al., "Radiomic MRI signature reveals three distinct subtypes of glioblastoma 
with different clinical and molecular characteristics, offering prognostic value beyond 
IDH1," Scientific Reports, vol. 8, no. 1, p. 5087, 2018/03/23 2018. 
[55] X. Zhang et al., "Long non-coding RNA expression profiles predict clinical phenotypes in 
glioma," Neurobiology of disease, vol. 48, no. 1, pp. 1-8, 2012. 
[56] W.-J. Zeng et al., "Integrative analysis of DNA methylation and gene expression identify 
a three-gene signature for predicting prognosis in lower-grade gliomas," Cellular 
Physiology and Biochemistry, vol. 47, no. 1, pp. 428-439, 2018. 
99 
 
[57] Y. Iwadate et al., "Molecular Classification and Survival Prediction in Human Gliomas 
Based on Proteome Analysis," Cancer Research, vol. 64, no. 7, pp. 2496-2501, 2004. 
[58] Y. Li et al., "Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI 
radiomics signature," European Radiology, pp. 1-9, 2018. 
[59] V. G. Kanas, E. I. Zacharaki, G. A. Thomas, P. O. Zinn, V. Megalooikonomou, and R. R. 
Colen, "Learning MRI-based classification models for MGMT methylation status 
prediction in glioblastoma," Computer Methods and Programs in Biomedicine, vol. 140, 
pp. 249-257, 2017. 
[60] H. Zhou et al., "MRI features predict survival and molecular markers in diffuse lower-
grade gliomas," Neuro-oncology, vol. 19, no. 6, pp. 862-870, 2017. 
[61] B. Niu et al., "Glioma stages prediction based on machine learning algorithm combined 
with protein-protein interaction networks," Genomics, 2019. 
[62] S. M. Reza, M. D. Samad, Z. A. Shboul, K. A. Jones, and K. M. Iftekharuddin, "Glioma 
grading using structural magnetic resonance imaging and molecular data," Journal of 
Medical Imaging, vol. 6, no. 2, p. 024501, 2019. 
[63] A. Chaddad, P. Daniel, S. Sabri, C. Desrosiers, and B. Abdulkarim, "Integration of 
Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-
Type Glioblastoma," Cancers, vol. 11, no. 8, p. 1148, 2019. 
[64] N. Beig et al., "Radiogenomic analysis of hypoxia pathway is predictive of overall survival 
in Glioblastoma," Scientific reports, vol. 8, no. 1, p. 7, 2018. 
[65] C. W. Law, Y. Chen, W. Shi, and G. K. Smyth, "voom: Precision weights unlock linear 
model analysis tools for RNA-seq read counts," Genome biology, vol. 15, no. 2, p. R29, 
2014. 
[66] G. Zararsiz et al., "voomDDA: discovery of diagnostic biomarkers and classification of 
RNA-seq data," PeerJ, vol. 5, p. e3890, 2017. 
[67] D. J. McCarthy, Y. Chen, and G. K. Smyth, "Differential expression analysis of multifactor 
RNA-Seq experiments with respect to biological variation," Nucleic acids research, vol. 
40, no. 10, pp. 4288-4297, 2012. 
[68] A. Oshlack, M. D. Robinson, and M. D. Young, "From RNA-seq reads to differential 
expression results," Genome biology, vol. 11, no. 12, pp. 1-10, 2010. 
100 
 
[69] W. Gardner, E. P. Mulvey, and E. C. Shaw, "Regression analyses of counts and rates: 
Poisson, overdispersed Poisson, and negative binomial models," Psychological bulletin, 
vol. 118, no. 3, p. 392, 1995. 
[70] M. Zanfardino et al., "Bringing radiomics into a multi-omics framework for a 
comprehensive genotype–phenotype characterization of oncological diseases," Journal of 
translational medicine, vol. 17, no. 1, p. 337, 2019. 
[71] Z. Shboul and K. Iftekharuddin, Efficacy of radiomics and genomics in predicting TP53 
mutations in diffuse lower grade glioma (SPIE Medical Imaging). SPIE, 2020. 
[72] X. Zhu et al., "Imaging-genetic data mapping for clinical outcome prediction via 
supervised conditional gaussian graphical model," in 2016 IEEE International Conference 
on Bioinformatics and Biomedicine (BIBM), 2016, pp. 455-459: IEEE. 
[73] V. Subramanian, M. N. Do, and T. Syeda-Mahmood, "Multimodal fusion of imaging and 
genomics for lung cancer recurrence prediction," arXiv preprint arXiv:2002.01982, 2020. 
[74] W. B. Pope, J. Sayre, A. Perlina, J. P. Villablanca, P. S. Mischel, and T. F. Cloughesy, 
"MR imaging correlates of survival in patients with high-grade gliomas," American 
Journal of Neuroradiology, vol. 26, no. 10, pp. 2466-2474, 2005. 
[75] D. A. Gutman et al., "MR imaging predictors of molecular profile and survival: multi-
institutional study of the TCGA glioblastoma data set," Radiology, vol. 267, no. 2, pp. 560-
569, 2013. 
[76] H. J. Aerts et al., "Decoding tumour phenotype by noninvasive imaging using a 
quantitative radiomics approach," Nature communications, vol. 5, p. 4006, 2014. 
[77] J. Guinney et al., "Prediction of overall survival for patients with metastatic castration-
resistant prostate cancer: development of a prognostic model through a crowdsourced 
challenge with open clinical trial data," The Lancet Oncology, vol. 18, no. 1, pp. 132-142, 
2017. 
[78] F. Passamonti et al., "A clinical-molecular prognostic model to predict survival in patients 
with post polycythemia vera and post essential thrombocythemia myelofibrosis," 
Leukemia, vol. 31, no. 12, p. 2726, 2017. 
[79] R. Shouval et al., "An Integrative Scoring System for survival prediction following 
umbilical cord blood transplantation in acute leukemia," Clinical Cancer Research, 2017. 
101 
 
[80] M. Kirienko et al., "EP-1362: Random forest analysis to predict Disease-Free Survival 
using FDG-PET and CT in Lung Cancer," Radiotherapy and Oncology, vol. 127, pp. S743-
S744, 2018. 
[81] L. Macyszyn et al., "Imaging patterns predict patient survival and molecular subtype in 
glioblastoma via machine learning techniques," Neuro-oncology, vol. 18, no. 3, pp. 417-
425, 2015. 
[82] H. Ohgaki, "Genetic pathways to glioblastomas," Neuropathology, vol. 25, no. 1, pp. 1-7, 
2005. 
[83] F. E. Bleeker, R. J. Molenaar, and S. Leenstra, "Recent advances in the molecular 
understanding of glioblastoma," Journal of neuro-oncology, vol. 108, no. 1, pp. 11-27, 
2012. 
[84] D. R. Johnson, H. E. Leeper, and J. H. Uhm, "Glioblastoma survival in the United States 
improved after Food and Drug Administration approval of bevacizumab: A population‐
based analysis," Cancer, vol. 119, no. 19, pp. 3489-3495, 2013. 
[85] A. Vartanian et al., "GBM's multifaceted landscape: highlighting regional and 
microenvironmental heterogeneity," Neuro-oncology, vol. 16, no. 9, pp. 1167-1175, 2014. 
[86] D. Yang et al., "Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift 
imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI," 
Neuroradiology, vol. 44, no. 8, pp. 656-666, 2002. 
[87] K. E. Emblem et al., "Glioma grading by using histogram analysis of blood volume 
heterogeneity from MR-derived cerebral blood volume maps," Radiology, vol. 247, no. 3, 
pp. 808-817, 2008. 
[88] M. Nicolasjilwan et al., "Addition of MR imaging features and genetic biomarkers 
strengthens glioblastoma survival prediction in TCGA patients," Journal of 
Neuroradiology, vol. 42, no. 4, pp. 212-221, 2015. 
[89] P. Prasanna, J. Patel, S. Partovi, A. Madabhushi, and P. Tiwari, "Radiomic features from 
the peritumoral brain parenchyma on treatment-naive multi-parametric MR imaging 
predict long versus short-term survival in glioblastoma multiforme: preliminary findings," 
European radiology, vol. 27, no. 10, pp. 4188-4197, 2017. 
102 
 
[90] S. Lacny et al., "Kaplan–Meier survival analysis overestimates cumulative incidence of 
health-related events in competing risk settings: a meta-analysis," Journal of clinical 
epidemiology, vol. 93, pp. 25-35, 2018. 
[91] Z. A. Shboul, L. Vidyaratne, M. Alam, and K. M. Iftekharuddin, "Glioblastoma and 
Survival Prediction," in International MICCAI Brainlesion Workshop, 2017, pp. 
International MICCAI Brainlesion Workshop 358-368: Springer. 
[92] Z. A. Shboul, M. Alam, L. Vidyaratne, L. Pei, M. I. Elbakary, and K. M. Iftekharuddin, 
"Feature-Guided Deep Radiomics for Glioblastoma Patient Survival Prediction," Frontiers 
in Neuroscience, vol. 13, 2019. 
[93] T. Leung and J. Malik, "Representing and recognizing the visual appearance of materials 
using three-dimensional textons," International journal of computer vision, vol. 43, no. 1, 
pp. 29-44, 2001. 
[94] S. Reza and K. Iftekharuddin, "Multi-fractal texture features for brain tumor and edema 
segmentation," in Medical Imaging 2014: Computer-Aided Diagnosis, 2014, vol. Proc. 
SPIE 9035, p. 903503: International Society for Optics and Photonics. 
[95] L. Vidyaratne, M. Alam, Z. Shboul, and K. Iftekharuddin, "Deep learning and texture-
based semantic label fusion for brain tumor segmentation," in Medical Imaging 2018: 
Computer-Aided Diagnosis, 2018, vol. 10575, p. 105750D: International Society for 
Optics and Photonics. 
[96] K. M. Iftekharuddin, W. Jia, and R. Marsh, "Fractal analysis of tumor in brain MR images," 
Machine Vision and Applications, vol. 13, no. 5-6, pp. 352-362, 2003. 
[97] A. Islam, K. M. Iftekharuddin, R. J. Ogg, F. H. Laningham, and B. Sivakumar, 
"Multifractal modeling, segmentation, prediction, and statistical validation of posterior 
fossa tumors," in Medical Imaging 2008: Computer-Aided Diagnosis, 2008, vol. Proc. 
SPIE 6915, p. 69153C. 
[98] S. Ahmed, K. Iftekharuddin, R. Ogg, and F. Laningham, "Efficacy of texture, shape, and 
intensity features for robust posterior-fossa tumor segmentation in MRI," in Medical 
Imaging 2009: Computer-Aided Diagnosis, 2009, vol. 7260, p. 726020: International 
Society for Optics and Photonics. 
[99] L. Han and M. R. Kamdar, "MRI to MGMT: predicting methylation status in glioblastoma 
patients using convolutional recurrent neural networks," in Pacific Symposium on 
103 
 
Biocomputing. Pacific Symposium on Biocomputing, 2018, vol. 23, pp. 331-342: World 
Scientific. 
[100] J. Yu et al., "Noninvasive IDH1 mutation estimation based on a quantitative radiomics 
approach for grade II glioma," European radiology, vol. 27, no. 8, pp. 3509-3522, 2017. 
[101] H. Ding et al., "Prediction of IDH Status Through MRI Features and Enlightened 
Reflection on the Delineation of Target Volume in Low-Grade Gliomas," Technology in 
cancer research & treatment, vol. 18, 2019. 
[102] Z. Akkus et al., "Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas 
from MR Images Using Machine Intelligence," Journal of Digital Imaging, pp. 1-8, 2017. 
[103] S. R. van der Voort et al., "Predicting the 1p/19q co-deletion status of presumed low grade 
glioma with an externally validated machine learning algorithm," Clinical Cancer 
Research, p. 1127, 2019. 
[104] J. Wang et al., "Pretreatment MRI Radiomics Analysis Allows for Reliable Noninvasive 
Prediction of Survival and TERT Promoter Mutation in Lower-Grade Gliomas," Available 
at SSRN 3487723, 2019. 
[105] A. Islam, S. M. Reza, and K. M. Iftekharuddin, "Multifractal texture estimation for 
detection and segmentation of brain tumors," IEEE transactions on biomedical 
engineering, vol. 60, no. 11, pp. 3204-3215, 2013. 
[106] S. M. Reza, R. Mays, and K. M. Iftekharuddin, "Multi-fractal detrended texture feature for 
brain tumor classification," in Medical Imaging 2015: Computer-Aided Diagnosis, 2015, 
vol. Proc. SPIE 9414, p. 941410: International Society for Optics and Photonics. 
[107] R. Meier, S. Bauer, J. Slotboom, R. Wiest, and M. Reyes, "A hybrid model for multimodal 
brain tumor segmentation," Multimodal Brain Tumor Segmentation, vol. 31, pp. 31-37, 
2013. 
[108] A. Pitiot, A. W. Toga, N. Ayache, and P. Thompson, "Texture based MRI segmentation 
with a two-stage hybrid neural classifier," in Proceedings of the 2002 International Joint 
Conference on Neural Networks. IJCNN'02 (Cat. No. 02CH37290), 2002, vol. 3, pp. 2053-
2058: IEEE. 
[109] S. Bauer, T. Fejes, J. Slotboom, R. Wiest, L.-P. Nolte, and M. Reyes, "Segmentation of 
brain tumor images based on integrated hierarchical classification and regularization," in 
MICCAI BraTS Workshop. Nice: Miccai Society, 2012, p. 11. 
104 
 
[110] X. Feng, N. Tustison, and C. Meyer, "Brain Tumor Segmentation Using an Ensemble of 
3D U-Nets and Overall Survival Prediction Using Radiomic Features," Cham, 2019, pp. 
279-288: Springer International Publishing. 
[111] P. John, "Brain tumor classification using wavelet and texture based neural network," 
International Journal of Scientific & Engineering Research, vol. 3, no. 10, pp. 1-7, 2012. 
[112] N. Nabizadeh and M. Kubat, "Brain tumors detection and segmentation in MR images: 
Gabor wavelet vs. statistical features," Computers & Electrical Engineering, vol. 45, pp. 
286-301, 2015. 
[113] K. R. Kukurba and S. B. Montgomery, "RNA sequencing and analysis," Cold Spring 
Harbor Protocols, vol. 2015, no. 11, p. pdb. top084970, 2015. 
[114] M. D. Robinson and G. K. Smyth, "Small-sample estimation of negative binomial 
dispersion, with applications to SAGE data," Biostatistics, vol. 9, no. 2, pp. 321-332, 2007. 
[115] M. D. Robinson and G. K. Smyth, "Moderated statistical tests for assessing differences in 
tag abundance," Bioinformatics, vol. 23, no. 21, pp. 2881-2887, 2007. 
[116] M. D. Robinson, D. J. McCarthy, and G. K. Smyth, "edgeR: a Bioconductor package for 
differential expression analysis of digital gene expression data," Bioinformatics, vol. 26, 
no. 1, pp. 139-140, 2010. 
[117] S. Anders and W. Huber, "Differential expression analysis for sequence count data," 
Genome biology, vol. 11, no. 10, p. R106, 2010. 
[118] Y. Di, D. W. Schafer, J. S. Cumbie, and J. H. Chang, "The NBP negative binomial model 
for assessing differential gene expression from RNA-Seq," Statistical Applications in 
Genetics and Molecular Biology, vol. 10, no. 1, 2011. 
[119] K. Dong, H. Zhao, T. Tong, and X. Wan, "NBLDA: negative binomial linear discriminant 
analysis for RNA-Seq data," BMC bioinformatics, vol. 17, no. 1, p. 369, 2016. 
[120] D. Yu, W. Huber, and O. Vitek, "Shrinkage estimation of dispersion in Negative Binomial 
models for RNA-seq experiments with small sample size," Bioinformatics, vol. 29, no. 10, 
pp. 1275-1282, 2013. 
[121] R. Tibshirani, T. Hastie, B. Narasimhan, and G. Chu, "Class prediction by nearest shrunken 




[122] L. E. Jalbert et al., "Metabolic profiling of IDH mutation and malignant progression in 
infiltrating glioma," Scientific reports, vol. 7, p. 44792, 2017. 
[123] B. H. Menze et al., "The multimodal brain tumor image segmentation benchmark 
(BRATS)," IEEE transactions on medical imaging, vol. 34, no. 10, pp. 1993-2024, 2015. 
[124] S. Bakas et al., "Segmentation Labels and Radiomic Features for the Pre-operative Scans 
of the TCGA-LGG collection," The Cancer Imaging Archive, 2017. 
[125] S. Bakas et al., "Advancing The Cancer Genome Atlas glioma MRI collections with expert 
segmentation labels and radiomic features," Scientific data, vol. 4, p. 170117, 2017. 
[126] J. Reunanen, "Overfitting in making comparisons between variable selection methods," 
Journal of Machine Learning Research, vol. 3, no. Mar, pp. 1371-1382, 2003. 
[127] M. Vallières, C. R. Freeman, S. R. Skamene, and I. El Naqa, "A radiomics model from 
joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue 
sarcomas of the extremities," Physics in medicine and biology, vol. 60, no. 14, p. 5471, 
2015. 
[128] A. Ayache and J. L. Véhel, "Generalized multifractional Brownian motion: definition and 
preliminary results," ed: Springer, 1999. 
[129] A. Ayache and J. L. Véhel, "On the identification of the pointwise Hölder exponent of the 
generalized multifractional Brownian motion," Stochastic Processes and their 
Applications, vol. 111, no. 1, pp. 119-156, 2004. 
[130] Z. A. Shboul, S. M. Reza, and K. M. Iftekharuddin, "Quantitative MR Image Analysis for 
Brain Tumor," in European Congress on Computational Methods in Applied Sciences and 
Engineering, 2017, pp. 10-18: Springer. 
[131] T. Chen and C. Guestrin, "Xgboost: A scalable tree boosting system," in Proceedings of 
the 22nd acm sigkdd international conference on knowledge discovery and data mining, 
2016, pp. 785-794: ACM. 
[132] L. v. d. Maaten and G. Hinton, "Visualizing data using t-SNE," Journal of machine 
learning research, vol. 9, no. Nov, pp. 2579-2605, 2008. 
[133] M. Amadasun and R. King, "Textural features corresponding to textural properties," IEEE 
Transactions on systems, man, and Cybernetics, vol. 19, no. 5, pp. 1264-1274, 1989. 
[134] Y. Wang et al., "Patterns of tumor contrast enhancement predict the prognosis of anaplastic 
gliomas with IDH1 mutation," American Journal of Neuroradiology, 2015. 
106 
 
[135] M. Zhang, W. Ma, W. Wu, and A. Maher, "The MGMT promoter methylation is correlated 
with gene mutation of IDH1 and 1p19q in glioma," ed: AACR, 2016. 
[136] M. C. Zlatescu et al., "Tumor location and growth pattern correlate with genetic signature 
in oligodendroglial neoplasms," Cancer research, vol. 61, no. 18, pp. 6713-6715, 2001. 
[137] X. Ren et al., "Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets 
of brain tumors in Chinese patients," PloS one, vol. 7, no. 3, p. e32764, 2012. 
[138] K. Wang et al., "Regional specificity of 1p/19q co-deletion combined with radiological 
features for predicting the survival outcomes of anaplastic oligodendroglial tumor 
patients," Journal of neuro-oncology, pp. 1-9, 2017. 
[139] J. C. Marioni, C. E. Mason, S. M. Mane, M. Stephens, and Y. Gilad, "RNA-seq: an 
assessment of technical reproducibility and comparison with gene expression arrays," 
Genome research, vol. 18, no. 9, pp. 1509-1517, 2008. 
[140] A. Mortazavi, B. A. Williams, K. McCue, L. Schaeffer, and B. Wold, "Mapping and 
quantifying mammalian transcriptomes by RNA-Seq," Nature methods, vol. 5, no. 7, p. 
621, 2008. 
[141] A. H. Bakas S, Sotiras A, Bilello M, Rozycki M, Kirby JS, Freymann JB, Farahani K, 
Davatzikos C., "Advancing The Cancer Genome Atlas glioma MRI collections with expert 
segmentation labels and radiomic features," Nature Scientific Data [in press], 2017. 
[142] A. Colaprico et al., "TCGAbiolinks: an R/Bioconductor package for integrative analysis 
of TCGA data," Nucleic acids research, vol. 44, no. 8, pp. e71-e71, 2015. 
[143] D. A. Gutman et al., "Somatic mutations associated with MRI-derived volumetric features 
in glioblastoma," Neuroradiology, vol. 57, no. 12, pp. 1227-1237, 2015. 
[144] P. Metellus et al., "Absence of IDH mutation identifies a novel radiologic and molecular 
subtype of WHO grade II gliomas with dismal prognosis," Acta neuropathologica, vol. 
120, no. 6, pp. 719-729, 2010. 
[145] Y. Park et al., "Prediction of IDH1-mutation and 1p/19q-codeletion status using 
preoperative MR imaging phenotypes in lower grade gliomas," American Journal of 
Neuroradiology, vol. 39, no. 1, pp. 37-42, 2018. 
[146] S. Thust et al., "Apparent diffusion coefficient for molecular subtyping of non-gadolinium-
enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional 
region of interest analysis," European radiology, pp. 1-10, 2018. 
107 
 
[147] A. Maufroy, E. Chassot, R. Joo, and D. M. Kaplan, "Large-scale examination of spatio-
temporal patterns of drifting fish aggregating devices (dFADs) from tropical tuna fisheries 
of the Indian and Atlantic Oceans," PloS one, vol. 10, no. 5, 2015. 
[148] A. Vabalas, E. Gowen, E. Poliakoff, and A. J. Casson, "Machine learning algorithm 
validation with a limited sample size," PloS one, vol. 14, no. 11, 2019. 
[149] L. Pan et al., "Machine learning applications for prediction of relapse in childhood acute 
lymphoblastic leukemia," Scientific reports, vol. 7, no. 1, pp. 1-9, 2017. 
[150] W. Yang et al., "Sex differences in GBM revealed by analysis of patient imaging, 
transcriptome, and survival data," Science translational medicine, vol. 11, no. 473, p. 
eaao5253, 2019. 
[151] Y. Yuan et al., "Comprehensive characterization of molecular differences in cancer 
between male and female patients," Cancer cell, vol. 29, no. 5, pp. 711-722, 2016. 
[152] J. E. Ippolito, A. K.-Y. Yim, J. Luo, P. Chinnaiyan, and J. B. Rubin, "Sexual dimorphism 
in glioma glycolysis underlies sex differences in survival," JCI insight, vol. 2, no. 15, 2017. 
[153] M.-Y. Li et al., "Isocitrate dehydrogenase 1 gene mutation is associated with prognosis in 
clinical low-grade gliomas," PloS one, vol. 10, no. 6, 2015. 
[154] D. J. Brat et al., "Comprehensive, integrative genomic analysis of diffuse lower-grade 
gliomas," New England Journal of Medicine, vol. 372, no. 26, pp. 2481-2498, 2015. 
[155] A. Ebrahimi et al., "ATRX immunostaining predicts IDH and H3F3A status in gliomas," 
Acta neuropathologica communications, vol. 4, no. 1, p. 60, 2016. 
[156] T. Coolen‐Maturi and F. Coolen, "Non‐parametric predictive inference for the validation 
of credit rating systems," Journal of the Royal Statistical Society: Series A (Statistics in 
Society), vol. 182, no. 4, pp. 1189-1204, 2019. 
[157] P. Lambin et al., "Radiomics: extracting more information from medical images using 
advanced feature analysis," European journal of cancer, vol. 48, no. 4, pp. 441-446, 2012. 
[158] R. Jain et al., "Outcome prediction in patients with glioblastoma by using imaging, clinical, 
and genomic biomarkers: focus on the nonenhancing component of the tumor," Radiology, 
vol. 272, no. 2, pp. 484-493, 2014. 
[159] Bakas S et al., "Segmentation Labels and Radiomic Features for the Pre-operative Scans 
of the TCGA-GBM collection," The Cancer Imaging Archive, 2017. 
108 
 
[160] S. Rathore, H. Akbari, M. Rozycki, S. Bakas, and C. Davatzikos, "NIMG-20. IMAGING 
PATTERN ANALYSIS REVEALS THREE DISTINCT PHENOTYPIC SUBTYPES OF 
GBM WITH DIFFERENT SURVIVAL RATES," ed: Oxford University Press US, 2016. 
[161] A. Materka and M. Strzelecki, "Texture analysis methods–a review," Technical university 
of lodz, institute of electronics, COST B11 report, Brussels, pp. 9-11, 1998. 
[162] R. M. Haralick, "Statistical and structural approaches to texture," Proceedings of the IEEE, 
vol. 67, no. 5, pp. 786-804, 1979. 
[163] X. Tang, "Texture information in run-length matrices," IEEE transactions on image 
processing, vol. 7, no. 11, pp. 1602-1609, 1998. 
[164] K. Turner, S. Mukherjee, and D. M. Boyer, "Persistent homology transform for modeling 
shapes and surfaces," Information and Inference: A Journal of the IMA, vol. 3, no. 4, pp. 
310-344, 2014. 
[165] L. Breiman, Random forests (Machine learning, no. 1). 2001, pp. 5-32. 
[166] L. Chato, E. Chow, and S. Latifi, "Wavelet Transform to Improve Accuracy of a Prediction 
Model for Overall Survival Time of Brain Tumor Patients Based On MRI Images." 
[167] P.-Y. Kao, T. Ngo, A. Zhang, J. Chen, and B. Manjunath, "Brain Tumor Segmentation and 
Tractographic Feature Extraction from Structural MR Images for Overall Survival 
Prediction," arXiv preprint arXiv:1807.07716, 2018. 
[168] M. Soltaninejad, L. Zhang, T. Lambrou, G. Yang, N. Allinson, and X. Ye, "MRI Brain 
Tumor Segmentation and Patient Survival Prediction Using Random Forests and Fully 
Convolutional Networks," in International MICCAI Brainlesion Workshop, 2017, pp. 204-
215: Springer. 
[169] A. Pierallini et al., "Radiological assessment of necrosis in glioblastoma: variability and 
prognostic value," Neuroradiology, vol. 40, no. 3, pp. 150-153, 1998. 
[170] M. Lacroix et al., "A multivariate analysis of 416 patients with glioblastoma multiforme: 
prognosis, extent of resection, and survival," Journal of neurosurgery, vol. 95, no. 2, pp. 
190-198, 2001. 
[171] M. V. Maldaun et al., "Cystic glioblastoma multiforme: survival outcomes in 22 cases," 








Zeina A. Shboul 
Department of Electrical and Computer Engineering 
Old Dominion University 
Norfolk, VA 23529 
 
Zeina A. Shboul joined the Vision Lab at Old Dominion University in Fall 2013. She 
received a Master’s degree in Electrical Engineering in 2011 from Jordan University of Science 
and Technology in Irbid, Jordan and a Bachelor’s degree in Electronics Engineering in 2007 from 
Yarmouk University in Irbid, Jordan. The motivation of her current research is to develop efficient 
non-invasive methods for Glioma grading and classification and predicting overall survival.  
Her research interests include biomedical image processing, gene expression analysis, 
molecular subtyping, machine learning, and computer vision. 
 
